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SUMMARY
Adenylate cyclase toxin (CyaA) is one of the many virulence factors produced 
by B.pertussis, the causative organism of whooping cough. The mechanisms 
governing the interaction of CyaA with target cells and the role toxin-activation plays in 
these are unclear. This study investigated these mechanisms.
For the purposes of this study CyaA was purified from B.pertussis 348 
(pRMBl) by a two step-process involving urea extraction of whole cells followed by 
calmodulin-agarose affinity chromatography. The purification of CyaA was confirmed 
by SDS-PAGE and Western blotting. The functional significance of toxin activation 
was studied by preparing activated and non-activated forms of CyaA from recombinant 
E.coli strains. Urea extraction from the recombinant strains yielded a 200kDa protein 
which was relatively free from contaminating host cell protein as determined by 
Coomassie blue staining. Enzymic assays showed that catalytically active forms of 
CyaA had been purified from the recombinant E.coli strains and from B.pertussis 348 
(pRMBl). The activated form of CyaA possessed toxic activity which was absent from 
the non-activated form.
Binding studies were employed to investigate the interaction of CyaA with 
various cell types. It was found that activated CyaA could bind to / associate with sheep 
erythrocytes in a time and dose-dependent manner. Studies revealed that binding 
increased even at very high doses of toxin, suggesting that the binding process is non- 
saturatable and therefore non-specific.
Regarding the specificity of interaction of CyaA with cells it was found that pre­
try p sinisation of sheep erythrocytes increased the susceptibility of the cells to the 
haemolytic activity of the toxin and this activity was directly dependent on the 
concentration of trypsin used to treat the erythrocytes. Trypsinisation of cells may have 
made membrane recognition sights more accessible for CyaA insertion and pore 
formation. The binding of CyaA to trypsinised cells was low compared to control cells
xvu
suggesting that the processes of binding and pore-formation are separable events. In 
this study it was found that none of the sugars tested; D-galactose, D-glucose, D- 
mannose, D-maltose, D-fucose or N-acetyl neuraminic acid (NANA), inhibited the 
binding of CyaA to sheep erythrocytes suggesting that these sugars may not play 
essential roles in toxin-cell interaction.
Interestingly, it was found that activated and non-activated derivatives of CyaA 
could both bind to / associate with sheep erythrocytes. However, binding of non- 
activated CyaA to cells from the murine macrophage cell line (J774.2) was much less 
when compared to the activated form. These results are the first evidence of differences 
in cell-affinity between activated and non-activated CyaA. No binding of activated or 
non-activated CyaA was detected with BHK or BL3 cells. It is possible that the 
solubilisation conditions of hypotonic lysis of these cell types may have resulted in the 
dissociation of bound toxin or that the assay was not sensitive enough to detect low 
levels of cell-bound toxin.
Sheep erythrocyte membrane proteins were investigated as potential receptors 
for CyaA. No binding was detected between CyaA and the membrane proteins isolated 
from sheep erythrocytes. To detect if CyaA interacts directly with glycolipid a thin-layer 
chromatogram overlay assay was developed. CyaA bound to a range of gangliosides 
(GMi, GDia, GDib, and GTib) and to some but not all of the components in a sheep 
erythrocyte lipid extract. These results suggest that glycolipids may be possible 
membrane recognition sites for CyaA.
Activated CyaA extracts were found to be lytic towards sheep erythrocytes and 
liposomes in a time and dose dependent manner. Unlike haemolysis the lytic effect of 
CyaA on liposomes proceeded without a lag period. This may be because liposomes do 
not have the same constraints on membrane integrity that erythrocytes have and can leak 
contents without lysis. Toxin activation was required for haemolytic and liposome 
permeabilising activities. This is further evidence of the essential role activation plays in 
the productive interaction of CyaA with cell membranes.
X V l l l
The activity of CyaA was much greater towards liposomes with a net negative 
charge than to liposomes with no net charge or a net positive charge, Gangliosides were 
not essential and other negatively charged lipids could fulfil the same function. These 
results suggest that the interaction of CyaA with membranes may be at the level of a 
charge-charge interaction whereby negatively charged moieties on the membrane 
surface act as the initial recognition sites.
SE C TIO N  1 
IN T R O D U C T IO N
Section 1 1 Introduction
1.1 CHARACTERISTICS OF BORDETELLA PERTUSSIS
1.1.1 Classification of Bordetella pertussis
Bordetella pertussis is a member of the genus Bordetella. Originally 3 species 
were assigned to this genus; Bordetella pertussis, the agent responsible for human 
pertussis; Bordetella parapertussis, which causes a mild, pertussis-like disease in 
humans and Bordetella bronchiseptica , which is primarily an animal pathogen but may 
infect humans (Moreno-Lopez, 1952).
Recently, Bordetella avium, associated with respiratory illness in birds 
(Kersters et al, 1984), Bordetella holmesii cultured from the blood of human patients 
with septicaemia (Weyant et a l , 1995) and Bordetella hinzii, isolated from poultry and 
humans (Vandamme et al, 1995) have also been identified as Bordetella spp. The 
Bordetellae are small Gram-negative, coccobacilli which are strictly aerobic and non- 
sporing. With the exception of B.holmesii, the Bordetellae are obligate parasites and 
pathogens of the upper respiratory tract. The different species can be differentiated by 
phenotypic characteristics such as motility, growth requirements and pathogenic 
tropism (reviewed by Parton, 1997). However, DNA homology studies have 
demonstrated that B .pertussis  is so closely related to B .parapertussis  and 
B.bronchiseptica that, rather than be considered as separate species, the organisms 
should be considered as subtypes of the same species (Kloos et al, 1981; Musser et al, 
1986). The other 3 members of the genus, B.avium, B.holmesii, and B.hinzii, are 
distinct from these subspecies, and from each other, and can be considered as distinct 
species (Vandamme et a l , 1995; Weyant et a l , 1995).
1.1.2 Growth characteristics of Bordetella pertussis
B.pertussis was first described by Bordet and Gengou (1906) who isolated the 
organism on a glycerol-potato-blood medium. The organism is a non-motile, oxidase
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positive, Gram-negative coccobacillus which grows optimally at 35-37®C. Originally it 
was thought that B.pertussis had complex growth requirements, requiring supplements 
such as blood, but it is now known that it can be grown on media containing just a few 
amino acids, growth factors and salts (Stainer and Scholte, 1971; reviewed by Stainer, 
1988). However the organism is sensitive to growth inhibition by peptone, sulphur, 
peroxide, manganese, and fatty acids (Pollock, 1947 and 1949; Proom, 1955; Rowatt, 
1957). A novel medium containing the cyclodextrin MeCD (2,6-O-dimethyl p- 
cyclodextrin) has now been developed which stimulates growth, even from small 
inocula of B.pertussis by neutralising growth inhibitors. This medium is of particular 
use because it promotes production of virulence factors which is of advantage in 
vaccine production and studies into the mechanisms of B.pertussis pathogenicity 
(Imaizumi etal, 1983 and 1984).
Importantly, B.pertussis grows in any of 4 serological phases (Phase I-IV) 
when cultured in vitro. Upon successive subculture, fresh isolates of B.pertussis are 
converted from phase I to phase IV, characterised by loss of haemolytic activity and an 
alteration in antigenic profile and colony morphology (Leslie and Gardner, 1931). The 
vimlence potential of B.pertussis is environmentally regulated (Lacey et al, 1960). It is 
believed that the different phases displayed in vitro are a visual demonstration of the 
phase variation, antigenic modulation and serotypic variation which may occur in the 
clinical manifestation of pertussis (see section 1.3.3).
1.2 CLINICAL ASPECTS OF PERTUSSIS
1.2.1 Pathology of pertussis
Pertussis (whooping cough) was first described in the sixteenth century (cited 
by Holmes, 1940). Nowadays, pertussis is recognised as an endemic, and sometimes 
epidemic, upper respiratory tract disease of humans (Cherry, 1988). Even in this 
modern era, pertussis is a global disease which is responsible for 60 million cases and
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half a million deaths annually worldwide (Muller et al, 1986). Mortality is highest in 
unimmunised infants, particularly in developing countries. The importance of pertussis 
as a disease has stimulated studies into its pathogenicity. Bordetella pertussis is the 
causative organism of whooping cough, although B.parapertussis  and even 
B.bronchiseptica, albeit very rarely, may also cause the disease (Mertsola, 1985; 
Woolfrey and Moody, 1991).
The disease is transmitted by close contact with infected individuals, via 
respiratory secretions. The most infectious period is during the first week of the illness 
when the organism is most easily isolated (Hodder and Mortimer, 1992). There have 
been reports of transmission from people with a sub-clinical infection (Long et al, 
1990) although the significance of this remains open to debate (Krantz et a l , 1986).
Classical pertussis, the most common form of infection, generally lasts 4 to 8 
weeks and presents itself as a disease of three stages, (catarrhal stage, paroxysmal stage 
and convalescent stage) although these stages do overlap. The most infectious stage is 
the catarrhal stage which lasts from 7-10 days. Patients present with a mild, non­
specific cough, rarely accompanied by fever, which increases in severity with time. The 
disease then progresses into the paroxysmal stage, punctuated by bouts of paroxysmal 
coughing which are terminated by the distinctive 'whoop' resulting from a vigorous 
inspiration of air (Cherry, 1988). This paroxysmal stage usually lasts for several 
weeks, but may last for a number of months with the paroxysms becoming less 
frequent and less severe, as patients convalesce (Cherry, 1988; Walker, 1988).
Morbidity and mortality are caused by complications, usually arising during the 
paroxysmal stage of pertussis. Respiratory, cerebral and haemorrhagic sequelae are the 
major causes of long-term illness and loss of life (Hodder and Mortimer, 1992). 
Secondary infections may also occur as a result of damage to the airways (Swansea 
Research Unit, 1985). Complications are manifested most commonly, and most 
severely in young infants and in particular babies < 1 year old (Farizo et al, 1992).
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1.2.2 Diagnosis and treatment of pertussis.
Pertussis is usually diagnosed on the clinical basis of a persistent cough for 14 
days (Patriarca et a l , 1988), accompanied by signs of lymphocyte proliferation, and 
isolation of B.pertussis from nasophyrangeal swabs (Onorato and Wassilak, 1987). 
However positive culture is only achieved in about 80% of cases, which diminishes if 
the disease has progressed, patients have received antibiotics or had previous 
immunisation (Onorato and Wassilak, 1987).Other diagnostic tests such as fluorescent- 
labelled antibodies, DNA probes, and ELISA techniques have been investigated but so- 
far these give variable results (Viljanen et al, 1982; Onorato and Wassilak, 1987).
Erythromycin is the drug of choice for treatment of pertussis, particularly if 
given early in infection (Bergquist et al, 1985). Ampicillin, chloramphenicol, and 
tetracycline, have also been investigated as antibacterials, but they are not as effective as 
erythromycin (reviewed by Hodder, 1992). However, antibiotic treatment is usually 
given too late and after patients are already paroxysmal. Treatment will therefore not 
prevent the harmful sequelae which sometimes occur at this stage although it is of 
importance in preventing secondary infection. Also by this stage the toxins and factors 
eliciting damage to the immune system will have already been released by B.pertussis 
(see section 1.3). Mortality and morbidity could be alleviated if earlier diagnosis was 
achieved thereby facilitating the use of antibiotics when they were most effective. 
However, the best solution is prevention by vaccination (see below).
1.2.3 Vaccination against pertussis
1.2.3.1 Conventional whole-cell vaccine
The discovery of Bordetella pertussis as the causitive organism of pertussis 
(Bordet and Gengou, 1906), encouraged the developement of whole cell vaccines, 
against the disease (reviewed by Cherry, 1996). Mass vaccination was introduced in 
the United States in the 1950's and since then, vaccination programmes have been
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introduced world wide. Vaccination in the United States has reduced the incidence of 
pertussis considerably (Figure 1.1). The efficacy of whole-cell vaccine preparations 
vary from country to country but they are all produced empirically by killing and 
partially detoxifying concentrated B.pertussis cultures by heat, chemical means or both 
(Cherry, 1988).
Despite the obvious efficacy of vaccination in controlling pertussis uptake rates 
of the vaccine have fallen in recent years and since 1980 there has been a resurgence in 
both incidence and mortality due to the disease (Figure 1.1) The drop in vaccination 
levels have been fueled by concern over the safety of the currently available whole cell 
vaccines (Cherry, 1996). Safety fears have been raised because of local transient 
reactions and reports of long-term neurological damage and even death linked to 
vaccination (reviewed by Ross, 1988). Short term reactogenicity takes the form of local 
inflammation, fever and and unexplained crying which, although distressing, is not life 
threatening. However, reports of vaccine-related seizure and encephalopathy are of 
concern (Alderslade et a l , 1981; Fenichel, 1982). There is controversy as to whether 
the neurological side-effects are real or imaginary. Recent studies have concluded that 
'pertussis vaccine encephalopathy is a myth' (Shields et at, 1986; Griffin et al, 1990; 
Gale et a l , 1994).
1.2.3.2 Acellular pertussis vaccines
New pertussis vaccines have now been developed which do not have the short 
or long term complications associated with the whole cell vaccine. This should lead to 
improvements in the vaccine uptake rate within the population, with a corresponding 
reduction in the incidence of disease. Research has centered on acellular, component 
vaccines (Rappuoli, 1996).
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Figure 1.1 Incidence of whooping cough in the United States, by year, 1957-1990
Source, Hodder and Mortimer (1992)
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The most studied candidate antigens for acellular vaccines are pertussis toxin 
(PT) and filamentous haemagglutinin (FHA), thought to be involved in tissue 
intoxication and bacterial adhesion respectively (see below). The first acellular vaccine 
was developed in Japan (Sato et al, 1984) and a number of vaccines, using either 
chemically of genetically detoxified components, are now at different stages of 
development (Table 1.1). The search for an acellular vaccine has added impetus to the 
study of the virulence factors of B.pertussis and the role of these factors in the 
pathogenesis of whooping cough.
1.3 PATHOGENICITY OF BORDETELLA PERTUSSIS
Bordetella pertussis produces an aixay of virulence factors which are thought to 
have a variety of roles in the pathogenesis of whooping cough (Weiss and Hewlett, 
1986). Different factors are thought to be involved in adherence of the bacteria to the 
respiratory epithelium, avoidance of the host immune system, and tissue damage.
1.3.1 Adhesins of Bordetella pertussis
1.3.1.1 Filamentous haemagglutinin
Filamentous haemagglutinin (FHA) is a 220kDa protein loosely associated with 
the cell surface. FHA is the major adhesin of B.pertussis, and mediates attachment of 
the organism to epithelial cells in vitro and in animal models and also to macrophages 
(reviewed by Mooi, 1994). Unusually, FHA has at least three separate binding 
activities which have specificity for CR3 integrins of macrophages, ciliated cells and 
epithelial cells or the extracellular matrix (Locht et al, 1993). The binding specificities 
of FHA may have different roles at the different stages of pertussis.
Studies with mutants deficient in FHA demonstrated that FHA is required for 
optimal adherence of B.pertussis to ciliated respiratory cells in culture. Furthermore
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Table 1.1 Development of acellular pertussis vaccines (Source; Rappuoli, 1996)
Vaccine components Detoxification Method Clinical Trials Efficacy
PT Hydrogen peroxide Phase I, II, III 71%
Tetranitromethane Phase I, II ND
Fonnaldehyde Phase I, II, III 54%
Genetic Phase I, II ND
PT + FHA Formaldehyde Phase I, II, III 69%
Formaldehyde Phase I, II, III 58%
Glutaraldehyde Phase I, II, III NA
PT + FHA + 69K Fonnaldehyde Phase I, II, III 63.9%
Genetic Phase I, II, III 84.2%
PT + FHA + 69K+ AGG Foimaldehyde Phase I, II, III 85%
PT, pertussis toxin; FHA, filamentous haemagglutinin; 69K, 69 kDa antigen; AGG, agglutinogens 
ND, not determined; NA, not available
Section 1 9 Introduction
when FHA was added exogenously to the FHA" mutant strains, adherence was restored 
(Tuomanen and Weiss, 1985). Strains carrying mutations in FHA are able to colonise 
the lungs but cannot persist in the upper respiratory tract of mice (Kimura et al, 1990; 
Mooi et al, 1992). These results suggest that FHA may be important in the initial stages 
of adherence but may be of less importance in colonisation of the lungs.
1.3.1.2 Fimbriae
Bordetella pertussis produces 2 types of proteinaceous fimbriae; agglutinogen 2 
and 3. B.pertussis is unusual in that a particular strain may produce either type of 
fimbriae, both types or none (reviewed by Tuomanen, 1988). Fimbriae are of 
importance in mediating attachment of B.pertussis to various cell types in vitro, but 
their role in pathogenesis remains unclear (Mooi, 1994). Mutants lacking fimbriae 
retain their ability to colonise the nasopharynx and lung but are less able to colonise the 
trachea when compared to wild-type B.pertussis in the mouse model of infection 
(Mooi, 1992). However, non-fimbriated B.pertussis can adhere to a number of cell 
types including ciliated cells, suggesting fimbriae may not be essential for adherence. 
There is also some evidence that fimbriae are involved in promoting adhesion to and 
subsequent invasion of macrophages by B.pertussis (Mooi, 1994).
1.3.1.3 Processed outer-membrane proteins
Bordetella pertussis possesses at least three outer membrane proteins 
synthesised as large precursor polypeptides which are proteolytically cleaved at both the 
C- and N-termini before insertion into the outer cell membrane. The mature proteins 
travel anomalously on denaturing gels and all contain RGD motifs which are thought to 
facilitate binding to target cells (Charles et al, 1994; Fernandez and Weiss, 1994; Finn 
and Stevens, 1995).
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Pertactin (P.69) is the protype of the family and has an apparent molecular 
weight of 69kDa as determined by SDS-PAGE (Montarez et al, 1985). Pertactin is 
important to B.pertussis for its attachment to and invasion of human cells (Leininger et 
al, 1991; Roberts et al, 1991). For this reason pertactin is being considered for 
inclusion in acellular pertussis vaccines (Rappuoli, 1996).
Recently, tracheal colonisation factor (TCF) and BrkA have been identified in 
B.pertussis (Fernandez and Weiss, 1994; Finn and Stevens, 1995). TCF is 
synthesized as a 68kDa protein and after proteolytic cleavage is retained in the 
membrane. A mutant of B.pertussis lacking TCF had significantly reduced ability to 
colonise the trachea when compared to the wild type strain but was still able to survive 
deeper in the lungs (Finn and Stevens, 1995).
Also produced by B.pertussis is BrkA. This protein shares sequence homology 
with pertactin and TCF (Fernandez and Weiss, 1994). B.pertussis mutants deficient in 
BrkA were less virulent, less adherent and more sensitive to killing by human serum 
(Fernandez and Weiss, 1994). These results suggest that BrkA may be an important 
virulence factor of B.pertussis with roles in both colonisation and resistance to host 
immunity.
1.3.2 Toxins produced by Bordetella pertussis
1.3.2.1 Tracheal cytotoxln
It is believed that the characteristic pathology of whooping cough: destruction of 
the ciliated respiratory epithelium, with corresponding effects on muco-cilliary function 
may lead to the generation of the paroxysmal cough associated with the disease (Olson, 
1975). Studies on hamster tracheal rings demonstrated that a fraction isolated from the 
supernatant of B.pertussis cultures can mimic this pathology (Goldman et al, 1982). 
The so-called tracheal cytotoxln (TCT) has been subsequently purified and consists of a 
disaccharide tetra-peptide subunit of peptidoglycan (Cookson et al, 1989). TCT causes
Section 1 11 Introduction
ciliated cell-specific respiratory tract pathology in vitro that is indistinguishable from 
the pathology seen in infection. The toxin also inhibits DNA synthesis of respiratory 
epithelial cells (Cookson et al, 1989). TCT may contribute directly to the pathology of 
pertussis by damaging the respiratory epithelium thereby allowing B.pertussis to 
multiply without mucociliary clearance.
1.3.2.2 Dermonecrotic toxin
Dennonecrotic toxin (DNT) is a heat-labile 140 kDa polypeptide localised in the 
cytoplasm of B.pertussis and only released by disruption of cells (Cowell et al, 1979; 
Zhang and Sekura, 1991). The protein is characterised by its ability to cause 
dermonecrotic lesions when injected into various animals (Livey and Wardlaw, 1984; 
Par ton, 1985). The role of DNT in the pathogenesis of whooping cough is uncertain 
since mutants lacking DNT retain their virulence in the infant mouse model of infection 
(Weiss and Goodwin, 1989). However, a related dermonecrotic toxin from Bordetella 
parapertussis has been reported to cause vasoconstriction in cell lines and organ strips 
and it has been suggested that DNT may play a role in the early stages of whooping 
cough by vasoconstriction of peripheral arterioles leading to localised inflammation and 
general respiratory degeneration (Endoh e ta l , 1988; Nakase and Endoh, 1988).
1.3.2.3 Lipo-oligosaccharide
Two types of lipo-oligosaccharide (LOS) have been described in B.pertussis, 
each consisting of a lipid A and oligosaccharide core, but no extensive O-antigen chain 
(reviewed by Chaby and Caroff, 1988). As well as possessing typical endotoxic 
activities such as general toxicity, pyrogenicity and adjuvanticity, the LOS of 
B.pertussis can also induce B-cell mitogenicity and polyclonal B-cell activation (Girard 
et a l , 1981; Haeffner-Cavaillon et a l , 1982) and also possesses anti-viral and anti­
bacterial activities (Ayme, 1980).
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1.3.2.4 Pertussis toxin
Pertussis toxin (PT) is the most extensively studied virulence factor of 
B.pertussis. PT is a 105 kDa hexameric protein composed an enzymically active A- 
subunit (PTA), and a B-oligomer (PTB), made up of 5 subunits (32, S3, S4 and S5 in 
a 1:1:2:1 ratio), which is responsible for binding of the toxin to mammalian cells 
(Tamura, 1982). PT binds to carbohydrate moieties on target-cell surface 
glycosphingolipids or glycoproteins via the B-oligomer. This facilitates entry of the 
enzymic subunit into the cell (Hausman and Burns, 1992; Tyrell et al, 1989). Once 
inside the cell the toxin exerts its effects by catalysing the transfer of an ADP-ribose 
moiety of NAD to a family of GTP-binding regulatory proteins. The altered G-proteins 
are unable to function normally in signal transduction. It is generally believed that the 
numerous biological activities described for pertussis toxin result from its effects on 
cellular signal transduction (Krueger and Barbieri, 1995; Kaslow and Burns, 1992).
Despite the multitude of effects PT has on mammalian cells the role of PT in 
pertussis remains unclear. PT may exert its effect by inhibiting the cells of the immune 
sytstem. PT may also be an important adhesin for B.pertussis. Mutants lacking PT do 
not adhere to human-ciliated cells. Exogenous addition of PT to such mutants restores 
adhernce (Tuomanen, 1988). Despite the debate about the specific role of PT in 
pertussis , its role as a virulence factor is not in doubt (Weiss and Hewlett, 1986).
1.3.2.5 Adenylate cyclase toxin
The toxin can penetrate mammalian cells where it is stimulated by host cell 
calmodulin to induce supraphysiological levels of intracellular cyclic adenosine 
monophosphate (cAMP) (Confer et al, 1984). The toxin can also lyse erythrocytes by 
colloid osmotic lysis (Ehrmann et al, 1991). Adenylate cyclase toxin (CyaA) is post- 
translationally activated and secreted by novel mechanisms and is a member of RTX
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family of toxins (Welch et al, 1991) produced by other Gram-negative bacteria (see 
section 1.4.).
Demonstration of CyaA as an important virulenee factor has been facilitated by 
the use of transposon (Tn5) mutants of B. pertussis. These mutants lacking adenylate 
cyclase as well as haemolytic activity are avirulent in an infant mouse model (Weiss et 
a l , 1983). In addition to implicating CyaA in pathogenesis, this was the first evidence 
that the adenylate cyclase and haemolysin were products of the same locus, later 
confirmed by Glaser and co-workers (Glaser et a l , 1988b). Recently it has been shown 
that CyaA is required for lethal infection of mice and cya A mutants are rapidly cleared 
from the lungs of intra-nasally challenged neonatal mice (Weiss and Goodwin, 1989; 
Goodwin and Weiss, 1990). Furthermore, both invasive and adenylate cyclase enzymic 
activities are required for colonisation of the mouse respiratory tract (Khelef et al, 
1992). These results stress the importance of adenylate cyclase toxin as a colonisation 
factor. The toxic activity of CyaA impairs the functions of a number of immune effector 
cells, and it is believed that CyaA may be involved in immune evasion during pertussis 
infection (Confer and Eaton, 1982).
1.3.3 Regulation of virulence by Bordetella pertussis
The expression of the virulence determinants of B.pertussis is subject to phase 
variation and antigenic modulation (Robinson et al, 1986). At a frequency of 10" ,^ 
B.pertussis can spontaneously and permanently change its phenotype between at least 
4 phases (Leslie and Gardner, 1931; Weiss and Falkow, 1984)). The phase change is 
seemingly sequential and is characterised by the loss of virulence and virulence 
determinants such CyaA, PT, FHA and outer membrane proteins (Weiss and Falkow,
1984).
B.pertussis is also subject to antigenic modulation in response to environmental 
conditions (Lacey et al, 1960). Changes in certain environmental stimuli such as
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temperature and the concentrations of various salts and acids can, reversibly, convert 
organisms from virulent to avirulent modes with a concomitant loss of virulence factors 
(Coote and Brownlie, 1988).
Phase variation and antigenic modulation in B.pertussis are underpinned by 
regulatory control mechanisms. The isolation of mutants of B.pertussis which were 
deficient in production of all virulence factors suggested that expression of these factors 
was under the control of a single genetic locus (Weiss et al, 1983). Subsequently, it has 
been found that virulence gene expression of B.pertussis is controlled by the products 
of the bvg A and bvg S loci. In this two-component regulatory system Bvg S acts as a 
sensor to detect changes in the external environment such as an increase in temperature 
and phosphorylates Bvg A. Phosphorylated Bvg A promotes expression of virulence 
activated genes (yag ) such as CyaA, PT and FHA, and represses the expression of 
virulence repressed genes {vrg ) as reviewed by Stibitz and Miller (1994).
Regulation allows B.pertussis to detect changes in the external environment 
and adapt by changing its phenotype. Differential production of virulence factors such 
as adhesins may be important in facilitating adherence of B.pertussis to different cell 
types during the different stages of pertussis.
1.3.4 Mechanisms of pathogenicity in pertussis
Considerable research has been carried out into the individual virulence factors 
of B.pertussis with respect to their chemical nature, genetics, immunogenicity and in 
particular their biological activities on cells and in animal models (reviewed by Wardlaw 
and Parton, 1988). However, the relevance of these activities in vivo and the 
mechanisms by which virulence detenninants co-operate with each other are unknown.
From the evidence available a model (Figure 1.2) has been proposed for the 
involvement of the virulence factors in the different stages of pertussis (Wardlaw and 
Parton, 1988). When the bacteria infect their host they attach to the ciliated respiratory
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Figure 1.2 Model for the sequence o f events in pertussis ^
The bacterial components involved are FHA, filamentous haemagglutinin; Agg, 
Fimbrial agglutinogens; PRN, pertactin; OMP, processed outer membrane proteins; 
PT, pertussis toxin; LOS, lipooligosaccharide; ACT, invasive adenylate cycalse activity 
of adenylate cyclase toxin; HLY, haemolytic activity of adenylate cyclase toxin; TCT, 
tracheal cytotoxin; DNT, dermonecrotic toxin, 
a (Adapted from Parton, 1997)
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epithelium of the airways and lungs via a co-operative mechanism between their 
adhesins (FHA, fimbriae, PT and outer membrane proteins). It is thought that the 
adherent bacteria liberate their toxic factors (ACT, TCT, PT, DNT, LOS) to facilitate 
persistence. The toxins probably act together to cause localised tissue damage to the 
ciliated epithelium and to inhibit immune effector cells therebye preventing clearance by 
the action of the mucocilliary escalator and by cell-mediated immunity respectively 
(Figure 1.2). B.pertussis may also establish an internal reservoir for infection as 
shown by its ability to survive intracellularly in various cell types (Ewanowich et al, 
1989; Lee et al, 1990). Recently it has been found that other Bordetella spp can 
survive and grow outside their hosts in low nutrient environments (Porter and 
Wardlaw, 1993). This may reflect mechanisms by which bordetellae in general 
maintain an external reservoir for infection.
1.4 ADENYLATE CYCLASE TOXIN OF BORDETELLA PERTUSSIS
1,4.1 History
Fishel and co-workers were the first group to discover that Bordetella pertussis 
produced a factor which had adenylate cyclase activity (Fishel et a l , 1970). In order to 
study the role of the adenylate cyclase in pathogenesis and its mode of action a number 
of investigators have subsequently attempted to purify it. Initial attempts to purify the 
toxin revealed a variety of forms ranging from 45 -700 kDa (Hewlett and Wolff, 1976; 
Shattuck et a l , 1985; Kessin and Franke, 1986).
More recently, significant purification has been achieved and from this it is 
apparent that the adenylate cyclase exists in two forms: a 43-50 kDa form which is 
found in culture supernates, and has only catalytic activity, and a 200-220 kDa form, 
termed invasive adenylate cyclase which posseses enzymic activity, and can enter 
mammalian cells where, stimulated by host-cell calmodulin, it elevates intracellular 
cyclic AMP levels (Rogel et a l , 1989; Bellalou et a l , 1990; Leusch et a l , 1990).
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Rogel and co-workers demonstrated that the two forms were immunologically related 
suggesting the smaller form was derived from the degradation of the larger form (Rogel 
et al , 1988). This was confirmed when it was demonstrated that the smaller form 
conesponded to the amino terminal portion of the larger precursor (Ladant et a l , 1989).
Cloning and sequencing of the adenylate cyclase gene, cya A, has indicated that 
the toxin is coded for by an open reading frame of 1706 codons, the product of which 
is a bifunctional protein (Cya A) with both invasive adenylate cyclase and haemolytic 
activities. (Glaser e ta l , 1988). Cya A displays low specificity, is toxic to a wide range 
of nucleated cells (Confer and Eaton, 1982) and haemolytic to erythrocytes (Rogel et al,
1991) from a number of species (see section 1.5).
1.4.2 Homology with the RTX-family of toxins
Cloning and sequencing of adenylate cyclase toxin genes from B.pertussis has 
also revealed that the toxin shows genetic similarity to the RTX family of toxins which 
are produced by other Gram-negative pathogens (reviewed by Welch, 1991 and Coote,
1992). The RTX toxins are important virulence factors to their producer organisms 
(Coote, 1992). The toxins are typified by Escherichia coli haemolysin (HlyA), 
Pasteurella haemolytica leukotoxin (LktA), Actinobacillus actinomycetemcomitans 
leukotoxin (AktA) and Actinobacillus pleuropneumoniae haemolysin (AppA) (Table
1.2). The group is expanding and recently related toxins have also been described in 
Actinobacillus suis, Proteus vulgaris, Morganella morganii, and in enteroaggregative 
and enterohaemorrhagic strains of E.coli (Koronakis et al, 1987; Lori et al, 1991; 
Baldwin etal, 1992; Schmidt et al, 1994).
The genes for synthesis, activation and secretion of the RTX toxins are 
organised in an operon structure (see below). These toxins are all synthesised as 
inactive precursors and activated post-translationally prior to secretion by a novel
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Table 1.2 Properties o f the representative RTX toxins a
Bacterium Toxin Amino acids Mr (kDa) No. of repeats
Bordetella pertussis Adenylate cyclase/ haemolysin (CyaA) 1706 177 41
Escherichia coli Haemolysin ( HlyA) 1023 110 16
Pasturella haemolytica Leukotoxin (LktA) 953 102 6
Actinobacillusactinomycetemcomitans Leukotoxin (AktA)
1055 116 12
Actinobacilluspleuropneumoniae Haemolysin (AppA) 956 103 9
a source, Coote (1992)
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secretion process (see sections 1.4.2.2 and 1.4.2.3). B.pertussis CyaA also shares a 
number of functional similarities with the RTX toxins (see sections 1.4.3 and 1.4.4)
1.4.2.1 Genetic structure and organisation
Synthesis, activation and secretion of CyaA requires the interaction of at least 
five gene products arranged in an operon structure. The operon structure for production 
of CyaA is homologous to that of the RTX toxins so far described (Figure 1.3) and 
includes the stmctural gene encoding an inactive polypeptide {cya A), the gene involved 
in toxin activation {cya C) and cya B, cya D and cya B which are involved in toxin 
secretion (Glaser et al, 1988b; Masure et al, 1990; Barry et a l , 1991). The mechanisms 
of toxin activation and secretion are discussed in sections 1.4.2.2 and 1.4.2.3 
respectively. Cloning and sequencing of the genes controlling production of the other 
RTX toxins has revealed similar gene clusters containing contiguous C, A, B, and D 
genes with homologous products and functions (reviewed by Welch, 1991 and Coote, 
1992).
1.4.2.2 Toxin activation
Bordetella pertussis CyaA is synthesised as an inactive protoxin and requires 
the collaboration of the product of the cya C gene for activation (Barry et al, 1991). The 
cya C mediated activation is necessary for the invasive and haemolytic activities of 
CyaA (Rogel et a l , 1989; Betsou et a l , 1993). The other members of the RTX family 
of toxins are also synthesised as inactive precursors and require prior activation for full 
biological activity (Nicaud et a l , 1985; Wagner et al, 1988; Forestier and Welch 1990). 
This suggests that toxin activation is a prerequisite for a successful interaction of 
adenylate cyclase toxin and the other RTX toxins with target cells.
The molecular mechanism of activation of E.coli Hly A has been studied as a 
model for the activation the RTX toxins. Initial studies revealed that activation of HlyA
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Figure 1.3 Genetic organisation o f RTX  toxins determinants ^
The A gene corresponds to the structural (toxin) gene.The C gene products is required 
for toxin activation and the B and D gene products are required for secretion. A 
corresponds to operon of CyaA (Glaser etal, 1988a, 1988b; Barry et a l , 1991). B, 
C, D and E are the opérons controlling production of HlyA (Mackmann atal, 1988; 
Welch and Pellet, 1988), LktA (Lo et al, 1987; Strathdee and Lo, 1987), AktA 
(Kolodrubetz et a l , 1989; Lally et a l , 1989; Kraig et a l , 1990) and AppA (Chang et al,
1989) respectively (see text). Also shown are the catalytic (stippled region ) of CyaA, 
and the glycine rich repeat units of all the toxins. Arrows indicate the direction of 
transcription.
 ^ source Coote (1992)
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did not involve proteolytic C-terminal cleavage, glycosylation or phosphorylation 
(Nicaud et al, 1985; Felmlee et al, 1985; Koronakis et al, 1989). However, it was 
observed that activated Hly A had an altered migration on moderately denaturing SDS- 
PAGE gels, compared to unactivated HlyA (Nicaud et al, 1985; Wagner et al, 1988). It 
was also observed that activation and the altered electrophoretic mobility, were sensitive 
to phospholipase treatment, suggesting that phospholipids may have a role in the 
activation proess (Wagner etal, 1988). It has subsequently been shown that activation 
of HlyA by HlyC requires a cytsolic activating factor (Hardie et al, 1991) identified as 
acyl-carrier protein (laaartel et al, 1991). It is believed that HlyA is activated by the 
transfer of a fatty-acyl group from acyl carrier protein to HlyA. The activation site of 
HlyA has been localised by Pellet and co-workers who isolated a monoclonal antibody 
which only recognised the activated form of Hly A (Pellet et al, 1990). The epitope of 
this antibody was localised within the 6-turn domain of HlyA. Recently it has been 
found that activation of HlyA occurs by fatty acylation of two internal lysine residues 
(Stanley et al, 1994). It is thought that activation of CyaA may occur by a similar 
mechanism.
The C gene sequences are highly conserved among the RTX toxins and it is 
assumed that all toxins are modified by a similar mechanism (reviewed by Braun and 
Focareta, 1991). The structural similarity between the RTX toxins is exemplified by the 
finding that the C gene products from one toxin can activate the A gene products of 
others e.g. HlyC can activate LktA and AppA (Forestier and Welch, 1990; Gygi et al,
1990). However, CyaA cannot be activated by HlyC or LktC, suggesting that although 
the mechanism of activation of the RTX toxins may be similar, they are not identical 
(Rogel etal, 1989; Westrop etal, 1997). These differences may be important in 
determining the specificity or lack of specificity of CyaA and the other RTX toxins (see 
section 1.6)
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1.4.2.3 Toxin secretion
Export of proteins across the Gram-negative membrane is normally a two step 
process involving initial targeting to the inner membrane by a hydrophobic N-terminal 
signal sequence followed by transfer across the outer membrane by a specific transfer 
mechanism and is exemplified by cholera toxin (Hirst and Welch, 1986; Hirst and 
Holmgren, 1987). The predicted N-terminal sequences of CyaA and HlyA do not 
display the typical features of hydrophobic signal sequences and it has been shown that 
they are secreted by a novel mechanism (Felmlee et al, 1985; Glaser et al, 1988b; 
Holland 1990).
The secretion of HlyA has been studied in detail as a model for secretion of 
CyaA and the other RTX toxins. The secretion of HlyA is dependent upon the products 
of hly B, hly D and toi C , and an uncleaved C-terminal signal sequence (Koronakis et 
a l , 1989; Holland e ta l , 1990; Wandersmann and Delepelaire, 1990)/ HlyB, HlyD, 
and TolC are transmembrane proteins (Mackmann et a l , 1985; Blight and Holland,
1990). It is believed that they interact with the C-terminal signal sequence of HlyA to 
facilitate its transfer across the cytoplasmic and outer membranes (reviewed by Coote,
1992).
It has been shown that CyaA, can be efficiently secreted by E. coli, suggesting 
that the secretion machinery has a broad recognition profile (Masure, 1990). The B and 
D gene products of the Bordetella pertussis adenylate cyclase operon and the other 
RTX members show extensive homology (summarised by Welch, 1991) suggesting 
that these toxins are secreted in a similar manner to HlyA.
1.4.3 Functional domains of adenylate cyclase toxin
The adenylate cyclase toxin of B.pertussis is synthesised as a 1706 amino acid 
polypeptide and possesses invasive adenylate cyclase and haemolytic activities (Glaser 
et a l , 1988b). Cloning and site directed mutagenesis have shown that the toxin is
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composed of an N-terminal catalytic domain and a C-terminal channel-forming domain 
which is homologous to the RTX toxins and is required for haemolysis and delivery of 
the catalytic domain to target cells (Figure 1.4).
1.4.3.1 N-terminal catalytic domain
Studies have revealed that N-terminal 400 amino acids of adenylate cyclase 
corresponds to the calmodulin dependent catalytic portion of the toxin (Glaser et al, 
1988a; Ladant et al, 1989). Further analyses have shown that an N-terminal fragment 
(residues 1-235) of the enzymic domain contains the active site for catalysis , and that a 
C-terminal fragment (residues 236-399) contains the calmodulin binding domain 
(Ladant et al, 1989; Glaser et al 1989). Lysine 58 and Lysine 65, which are located in a 
putative ATP binding site, have been implicated in catalysis and Tryptophan-242 has 
an important role in calmodulin binding (Moller and Amons, 1985; Glaser et al, 1989 
and 1990)
1.4.3.2 C-terminal channel-forming domain
The C-teiTninal portion of CyaA (residues 400-1706) can independently act as a 
haemolysin (Sakamoto et al, 1992). This domain shows seqeunce homology with the 
RTX toxins (reviewed by Coote, 1992) and contains three highly conserved regions: a 
hydrophobic region, a region rich in 6-turns and a region which contains a variable 
number of glycine-rich tandem repeats (Figure 1.4).
Hydrophobicity plots of the amino acid sequence of CyaA have identified a 
200 residue hydrophobic region containing four putative membrane-spanning domains 
starting at amino acid 530 (Eisenberg et al, 1984). Homologous hydrophobic regions 
have been found in the other RTX toxins (Coote, 1992). Mutations altering the 
hydrophobicity of CyaA abolish its pore-forming ability and toxicity (Glaser et a l , 
1988b; Bellalou et a l , 1990). Studies with other RTX toxins such as HlyA (Ludwig
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Catalytic domain Channel-forming domain
1000ATP CaM 400
acyl
Catalytic domain I I II 6-turn region
Hydrophobic region Glycine-rich repeat region
Figure 1.4 Diagrammatic representation o f the domain structure o f B. pertussis 
adenylate cyclase toxin a. The first 400 N-terminal amino acids correspond to the
enzymic domain of CyaA. Within this domain, ATP and calmodulin (CaM) binding 
sites are shown (see section 1.4.3.1). The C-terminal amino acids show homology 
with the RTX cytolysins and are involved in channel formation in target cells. Also 
shown is the acyl-modification site involved in toxin activation (see section
1.4.2.2). N and C represent the N- and C- termini of the protein, 
a based on a model by Hanski (1989)
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et al, 1987 and 1988) and Lkt A (Cmz et a l , 1990) have yielded similar results. Also, 
peptides prepared from the hydrophobic region of Hly A, retain pore-forming ability 
(Oropeza-Wekerle et a l , 1992). These results have implicated the hydrophobic domains 
in pore formation (see section 1.4.4).
The hydrophobic region is followed by a region rich in p-turns which contains 
the putative acylation site required for activation (see section 1.4.2.2) of CyaA and 
HlyA (Stanley e ta l, 1994).
At the C-terminus of the CyaA and the other RTX toxins there is a region 
containing tandemly arranged glycine-rich nonapeptide repeat sequences from which 
their name was derived (Welch, 1991). The RTX toxins contain variable numbers of 
these repeats (Table 1.2). Rose et al (1995) have recently shown that the repeat 
region of CyaA can bind calcium and that binding to this region can induce a 
conformational change. Deletions within the repeat region of HlyA reduce or abolish 
haemolysis (Ludwig et al, 1988). It has also been demonstrated, with HlyA and LktA, 
that the repeats are actually involved in calcium binding and binding of the toxins to 
target cells (Ludwig et al, 1988; Boehm et al 1990a and 1990b). Analyses of the three 
dimensional structure of a similar repeat motif found in the alkaline protease of 
Pseudomonas aeruginosa have found that it eonstitutes a new type of calcium binding 
structure (Baumann et a l , 1993). From these studies with the other RTX toxins the 
repeat region appears to be involved in the calcium-dependent interaction of CyaA and 
the other RTX toxins with target cells (see section 1.4.4.4)
1.4.4 Interaction of adenylate cyclase toxin with mammalian cells
1.4.4.1 Pore formation by adenylate cyclase toxin
The RTX toxins such as E.coli HlyA, P .h a e m o ly tic a  LktA, 
A.pleuropneumoniae AppA, and A. actinomycetemcomitans AktA lyse target cells by 
formation of transmembrane pores (Bhakdi et al, 1980; Lalonde et al, 1988; 
Clinkenbeard et a l , 1989; Iwase et a l , 1990).
Section 1 2 6 Introduction
Similarly, B.pertussis CyaA destroys erythrocytes by colloid osmotic lysis 
(Ehrmann et a l , 1991). Studies with sheep erythrocytes have demonstrated haemolysis 
occurs after a lag period of 45-60 minutes (Ehrmann et a l , 1991; Rogel et a l , 1991). 
Osmotic protection studies have revealed that haemolysis by CyaA is brought about by 
the formation of pores with a diameter of approximately 0.6 nm (Ehrmann et a l , 1991). 
The toxin can also disrupt liposome membranes (Gordon et al , 1989).
There is still debate as to whether the pores formed in cell membranes by CyaA 
are generated by toxin monomers or oligomers. As the prototype of the RTX-toxin 
family E.coli HlyA has been used as a model to describe pore formation by CyaA and 
other RTX toxins. HlyA forms voltage-dependent, cation-selective and ion permeable 
transmembrane pores in erythrocyte membranes (Bhakdi et al, 1987; Menestrina et a l , 
1987; Menestrina, 1988; Eberspacher e ta l , 1989)
The pores formed display similar properties to other membrane-seeking 
bacterial toxins including the colicins (Schein et al , 1978), diphtheria toxin (Shiver 
and Donovan, 1987), botulinum and tetanus toxin (Shone et al, 1987; Hoch etal, 
1985). In contrast to the oligomeric pores formed by many cytolysins from Gram- 
positive organisms (Bhakdi and Tranum-Jensen, 1988) as well as complement (Bhakdi 
and Tranum-Jensen, 1987) and lymphocytolysins (Henkart, 1985), the pores formed 
by HlyA appear to be formed by toxin monomers (Jorgensen e ta l , 1980; Menestrina, 
1988). However in one study it has been reported that toxin molecules act co­
operatively to form oligomeric pores (Benz et a l , 1988). In this study Benz et al were 
unable to reconcile their findings with the observations of other researchers and it may 
be that the pores are generated from pre-formed oligomers.
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1.4.4.2 Invasive activity of adenylate cyclase toxin
In contrast to the other RTX toxins CyaA has toxic as well as lytie effects on 
mammalian cells. Confer and Eaton first demonstrated that CyaA could elevate cyclic 
AMP levels in maerophages by conversion of endogenous ATP to cAMP (Confer and 
Eaton, 1982). Since then a number of studies have demonstrated that CyaA is toxic to a 
wide range of cells, and in particular immune effector cells, leading to impairment of 
function (reviewed by Hewlett and Gordon, 1988). Further investigation has shown 
that intoxication is due to the activity of CyaA itself, rather than by activation of an 
intrinsic membrane-bound adenylate cyclase (Hanski and Farfel, 1985; Friedman et a l ,
1987). In contrast to haemolysis, which occurs after a lag period, intoxication by CyaA 
occurs immediately (Farfel etal, 1987; Friedman et al, 1987; Rogel et al, 1991). In 
these studies intracellular cAMP accumulated, inside CyaA treated cells, even when 
trypsin was present in the external medium (Farfel et a l , 1987; Friedman et a l , 1987). 
This was the first evidence that CyaA or at least the enzymic domain (see section 
1.4.3.1) penetrates target cells.
The enzymic activity of CyaA is activated by the eukaryotic regulatory protein, 
calmodulin (Wolff et al, 1980; Greenlea etal, 1982; Kilhoffer etal, 1983). Exogenous 
addition of calmodulin to CyaA blocks intoxication of target cells (Shattuck and Storm, 
1985). It has been suggested that the binding of calmodulin to CyaA outside cells may 
induce a conformational change, thus preventing the toxin from binding to or 
penetrating the cell membrane (Hanski, 1989). However, it has been found that 
exogenous addition of calmodulin actually potentiates haemolysis of sheep erythrocytes 
by CyaA (Rogel et a l , 1991). The differences in the toxic and haemolytic properties of 
CyaA, such as calmodulin and calcium requirement (see below) and kinetics (discussed 
above) suggest that the toxic and lytic activities of CyaA are separable and may be 
mediated by different domains of the toxin.
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1.4.4.3 Role of calcium in activities of adenylate cyclase toxin
In common with the other RTX toxins, CyaA is dependent on calcium for some 
of its biological activities. Hewlett and co-workers first demonstrated that CyaA was a 
calcium binding protein, and that binding of calcium altered the conformation of the 
toxin molecule (Hewlett et a l , 1991). Recently it has been found that the repeat motifs 
of CyaA can bind calcium inducing a conformational change (Rose et al, 1995). 
However, there is debate as to the exact role of calcium in the different stages of cellular 
attack by CyaA. The catalytic acticity of CyaA is calcium-independent (Greenlea et al, 
1982; Kilhoffer e ta l , 1983), whereas the invasive adenylate cyclase activity of CyaA 
requires calcium (Rogel et a l , 1991). The involvement of calcium in the lytic activity of 
CyaA is still a matter of controversy. The majority of studies have shown that the lytic 
activity of CyaA requires calcium (Gordon eta l, 1989; Ehrmann a/, 1991). 
However, Rogel and co-workers demonstrated that the binding of CyaA to sheep 
erythrocytes and subsequent haemolysis did not require calcium, and even occurred in 
the presence of the calcium-chelating agent, EDTA (Rogel e t a l , 1991). It is probable 
that CyaA encounters and binds calcium during growth of B.pertussis and purification 
of the toxin, and that results which suggests calcium-independence may be an artefact 
of this.
1.4.4.4 Molecular mechanisms for interaction of adenylate cyclase 
toxin with target cells
The process by which CyaA can form pores in cell membranes and also enter 
target cells, has still not been satisfactorily explained at the molecular level. Evidence 
so far has suggested that penetration occurs in consecutive steps involving initial cell 
binding, insertion and pore formation, and finally delivery of the catalytic domain 
leading to intoxication and/or cell lysis (Rogel and Hanski, 1992; Hewlett e t a l , 1993).
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The first step in the interaction of CyaA with the target cell is initial association 
with the cell surface. Binding to target cells does not reqiuire calcium or prior activation 
of the toxin (Rogel et a l , 1991; Hewlett et a l , 1993). This is in contrast to E.coli 
HlyA, which requires calcium and an intact repeat region (see section 1.4.3.1) to bind 
to target cells. It may be that the initial association of CyaA is a non-specific one (see 
section 1.4,5),
The next stage is insertion into the cell membrane and pore formation. The 
hydrophobic membrane spanning region (see section 1.4.3.1) of CyaA is believed to be 
involved in the formation of pores in the cell membrane (Bellalou et al, 1990). Toxin 
activation and high calcium concentrations are required for this stage (Rogel and 
Hanski, 1992; Hewlett et a l , 1993). Activation occurs by acylation of CyaA (see 
section 1.4.2.2), and this may reflect a mechanism of anchoring CyaA to cell 
membranes, analogous to the acylation of certain eukaryotic proteins which is thought 
to be involved in protein-protein and protein-lipid interactions (Towler et al, 1988; 
O'Dowd et al, 1989; Wedegaertner et al, 1993). Acylation may anchor CyaA in a 
position to allow calcium to induce a conformational change allowing the toxin to insert 
into the membrane (Hewlett et al, 1991 and 1993).
The next steps in the cellular attack by CyaA, intoxication due to invasive 
adenylate cyclase activity, and cell lysis, are separable events. Lysis requires relatively 
high concentrations of CyaA and occurs after a lag period, whereas intoxication is 
immediate and occurs in the presence of relatively low concentrations of CyaA (Rogel 
et al, 1991). It has been hypothesised that the invasive adenylate cyclase and haemolytic 
activities of CyaA are mediated by different domains of the toxin molecule (Rogel et al, 
1991). Meanwhile studies using agents which interfere with endocytosis, or prevent 
acidification of endosomes, have revealed that the mechanism of entry of the toxin 
does not involve receptor-mediated endocytosis (Gordon etal, 1988 ; Donovan et al,
1991). Rogel and Hanski have demonstrated that the catalytic domain is cleaved and 
released inside target cells (Rogel and Hanski, 1992). From this it has been
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hypothesised that the RTX toxin homologous channel-forming portion of CyaA forms 
a pore in target cell membranes (in an analogous manner to the other RTX toxins) 
whereupon the amino terminal catalytic domain is inserted and exerts its toxic effects 
(Rogel and Hanski, 1992). Lysis probably follows later when a sufficient number of 
pores have been formed. A hypothetical model for the interaction of CyaA with target 
cells, based on the evidence accumulated so far is shown in Figure 1.5
1.5 SPECIFICITY OF RTX TOXINS
Despite exhibiting structural and functional similarity, the RTX toxins display 
striking differences in their specificity. B.pertussis CyaA displays little specificity in 
terms of its lytic and toxic activities. CyaA is haemolytic to a broad range of cell types 
including erythrocytes from humans, sheep, rabbits and mice (Ehrmann et al, 1991; 
Rogel et a l , 1991) and also toxic to a wide range of nucleated cells such as human 
macrophages, monocytes and natural-killer cells and also rat pituitary cells and murine 
lymphoma cells (Confer and Eaton, 1982; Hewlett et al, 1983; Hanski and Farfel, 
1985; Weiss et a l , 1986). Similarly other RTX toxins such as E.coli HlyA and 
A.pleuropneumoniae AppA are non-specific. HlyA lyses erythrocytes and nucleated 
cells from a wide range of species (Cavalier et a l , 1984; Gadeberg and Orsklov, 1984; 
Bhakdi e ta l , 1989 ; Mobley et a l , 1989) and AppA is lytic towards erythrocytes from 
porcine, equine , bovine and human origin (Maudsey and Kada, 1981; Rosen dal et al,
1988) and toxic towards rabbit and porcine neutrophils and porcine macrophages 
(Bendixin eta l, 1981; Rosendal et a l , 1988).
However, other RTX toxins such as P.haem olytica  LktA and
A.actinomycetemcomitans Akt A, are highly specific. The activity of LktA is limited 
to ruminant leukocytes and platelets (Shewen and Wilkie, 1982; Clinkenbeard and 
Lipton, 1991), whereas Akt A is specific for leukocytes from certain primate species 
(Taichman ef <3/ , 1987).
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Figure 1.5 Hypothetical model fo r  the interaction o f adenylate cyclase 
toxin with target cells Adenylate cyclase toxin (CyaA) is activated post- 
translationally by acylation of a region in the C-terminal half of the protein. Activated 
(acylated) and non-activated forms of CyaA can both bind non-specificially to target 
cells. Non-activated CyaA is unable to penetrate the the cell membrane and therefore 
cannot mediate cell intoxication or lysis. The activated form of CyaA may anchor the 
toxin to a receptor wherebye calcium induces a conformational change facilitating 
penetration of the toxin into the cell via a trans-membrane pore formed by the 
hydrophobic region of the protein. The catalytic domain of the protein is delivered to 
the target cell by a cellular protease. Inside the cell the catalytic domain binds to 
calmodulin and is activated to convert ATP to cAMP, leading to cell intoxication. 
Formation of pores in the cell membrane may also lead to cell lysis.
 ^based on models by Rogel and Hanski (1992); Hewlett et al (1993).
absent
^ ^ ’“caaon
^cti Cya A
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According to these differences in specificity the RTX toxins can be divided into two 
distinct classes (see below).
Haemolysins - typified by HlyA, CyaA and AppA. The haemolysins have broad 
specificity and will lyse erythrocytes and nucleated cell types from a variety of species.
Leukotoxins - typified by Lkt A and Akt A. The leukotoxins are highly specific and 
their lethality is host and cell specific.
The molecular basis of the differences in specificity is unknown. Kraig and co­
workers compared the predicted primary amino acid sequences derived from cloned 
toxin genes from a number of RTX toxins (Ki'aig et a l , 1990). This study revealed no 
regions of homology within the haemolysin and leukotoxin classes of RTX toxin that 
could account for the differences in target cell specificity. Indeed the non-specific 
haemolysins AppA and HlyA are most closely related to the highly specific leukotoxins 
LktA and the Akt A respectively (reviewed by Welch, 1991). Thus, the primary amino 
acid sequences do not reflect differences in specificity. Instead, it is likely that the 
tertiary / domain structure of the toxins will determine the specificity of interaction of 
these toxins with target cells.
Recently, gene hybrids have been constructed between different RTX toxin 
genes to determine whether or not certain domains are involved in determining target 
cell specificity (Forestier and Welch, 1991; McWhinney et al, 1992). These studies 
found that the domains which determine erythrocyte and leukocyte lysis are indeed 
separate. However, these reports conflict on the precise location of the domains 
involved. Forestier and Welch generated a number of different hybrids between the hly 
A  and lkt A  genes and reported that a significant portion of the ruminant cell specificity 
of Lkt A resides in the amino terminal one fifth of the protein, while a region within the 
repeat region of Hly A is critical for cytolysis of nucleated cells but not haemolysis 
(Forestier and Welch, 1991). McWhinney and co-workers generated hybrids between
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app A  and Ikt A  and reported that the haemolytic and leukotoxic activities of App A 
were determined by different, perharps overlapping regions of the protein (McWhinney 
et al, 1992). However, in contrast to Forestier and Welch, McWhinney and co-workers 
reported that the leukocytic potential of AppA maps to the carboxy-terminal half of the 
protein. Further studies are required to determine if different domains are indeed 
involved in determining the degree of specificity of the various RTX toxins, and if so, 
which domains.
It has also been reported that specificity was dependent upon the RTX C-gene 
used for activation (Forestier and Welch, 1990). It is apparent that the specificity of the 
RTX toxins may be determined by differences in domain structure although as yet it is 
not clear which domains are ultimately involved. Specificity may or may not be 
dependent upon the process of activation. The generation of further gene hybrids and 
studies involving heterologous activation of RTX toxins should elucidate the domains 
involved in target cell recognition and the role activation plays in determining 
specificity.
1.6 CELLULAR RECEPTORS FOR BACTERIAL TOXINS
Biological receptors are defined as the binding-components on the cell surface 
which ultimately lead to the productive expression of toxicity of a particular toxin 
(Fidels e ta l , 1983) and biochemically defined as possessing specificity, high affinity, 
and saturatability (Cautrecasas, 1974). The majority of receptors for bacterial toxins 
are thought to involve carbohydrates (Fidels et al, 1983; Karlsson, 1989; Karlsson et 
al, 1991) present as glycoconjugates on glycolipids e.g. receptors for cholera toxin, 
botulinum toxin and tetanus toxin, or on glycoproteins e.g. receptors for diphtheria 
toxin and anthrax protective antigen (Table 1.3).
Carbohydrates, either linked to proteins or lipids, make up the major part of cell 
surfaces and are therefore primary collision partners for bacterial toxins. Cell surface
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T a b le  1 .3 R ep o r ted  m em bran e recep to rs  f o r  se lec ted  b a c te r ia l tox in s
Bacterium Toxin Target tissue Receptor Reference
V.cholerae Cholera toxin Small intestine Glycolipid Merritt et al, 1994a
E.coli Heat-labile toxin Intestine Glycoiipid Sixma eta l, 1992
C. botulinum Botulinum toxins Nerve membranes Glycolipid Takimazawa etal, 1986
C. tetani Tetanus toxin Nerve membranes Glycolipid Schiavo e ta l, 1991
S.dysenteriae Shiga toxin Large intestine Glycolipid Lindberg e ta l, 1986
B. pertussis Pertussis toxin Respiratory tract Sugars ^ Hausman & Burns, 1993
C. diphtheriae Diphtheria toxin Respiratory tract Glycoprotein Mekada et al, 1991
B.anthracis PA b ? Glycoprotein Escuyer & Collier, 1991
E.coli Heat-stable toxin Intestine Glycoprotein Dreyfus & Robertson, 1984
Reported to bind to sugars groups on glycolipids and glycoproteins 
Protective Antigen (PA)
Section 1 35 Introduction
glycolipids and glycoproteins vary between cells and from one host to another, and this 
is thought to explain the host- and cell-specificity of many pathogens and their 
particular toxins (Karlsson e ta l , 1989).
Few receptors have been formally identified at the molecular level. Recently, the 
three dimensional stucture of a number of toxin-receptor complexes has been achieved 
(Sixma et a l , 1992; Merritt et al, 1994a and 1994b; Stein et al, 1994). Of the receptors 
identified so far the majority of binding sites are internal carbohydrate residues of 
glycolipids or glycoproteins. Internal residues may be more susceptible to mutational 
shifts in receptor specificity, which is not possible with the functionally important 
terminal residues (Karlsson, 1989). The relevence of the binding affinities ascribed to 
toxins in vitro has still not been proven (Karlson, 1989). However, identification of 
further receptors and the domains of toxins involved in binding to these, will hopefully 
yield important information on the structure-function relationships and the mode of 
entry of bacterial toxins into eukaryotic cells. It has been hypothesised that toxins such 
as diphtheria toxin interacting with glycoproteins may enter cells by receptor-mediated 
endocytosis (Eidels et a l , 1983). Glycolipid receptors, which have a close proximity to 
the lipid bilayer itself, may facilitate direct penetration into the membrane (Karlsson,
1991).
1.6.1 Receptors for RTX toxins
Research into the interaction of the RTX toxins with target cells so far has been 
centered on the influence of the toxins themselves on specificity (see section 1.5). 
Research into the influence of the target cell and its membrane recognition sites, which 
will ultimately define whether or not there will be a productive expression of toxicity, 
has been limited. It is likely that the broad specificity haemolysins such as E.coli HlyA,
B.pertussis CyaA and A.pleuropnuemoniae AppA will interact with receptors 
common to a wide range of cell types, whereas the highly specific leukotoxins of
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P.haemolytica ?L\\.à. A.actinomycetemcomitans, will recognise receptors limited to 
particular cell types.
HlyA and AppA are active against artificial lipid vesicles, suggesting that these 
toxins can also interact directly with the lipid bilayer (Lalonde et a l , 1988; Menestrina, 
1988; Menestrina et al, 1987). Benz et al (1989) reported that permeabilisation of 
liposomes by HlyA was dependent upon the lipid composition. In this study, pore 
formation by HlyA was much higher in liposomes composed of asolectin (a crude lipid 
mixture from soyabean) than pure phospholipids. Hence, asolectin may contain a 
receptor for HlyA. However, Menestrina (1988) has reported that HlyA can 
permeabilize liposomes composed of pure phospholipids.
With respect to CyaA, it has been observed that intoxication of Chinese 
Hamster Ovary (CHO) cells by CyaA is unaffected by pre-treatment of the cells with 
trypsin or cyclohexamide suggesting that the toxin does not interact with cell-surface 
proteins (Gordon et al, 1989). Also, CyaA can permeabilise artificial lipid vesicles 
suggesting it can interact directly with the lipid bilayer (Gordon et al, 1989). The 
limited research carried out so far on CyaA has implicated gangliosides as putative 
membrane receptors. Gable and co-workers demonstrated that toxicity of CyaA 
towards polymoiphonuclear leukocytes could be inhibited by pre-treating the cells with 
neuraminidase or by incubation of the toxin with bovine brain gangliosides (Gable et al,
1985). Gordon et al (1989) subsequently carried out a more extensive study of the 
target cell recognition sites for CyaA and showed that pre-incubation of CyaA with 
different gangliosides inhibited subsequent intoxication of CHO cells by the toxin.
Charge-charge interactions may be important in the interaction of Cya A with 
target cells. Rapitis et al (1989) reported that cationic molecules inhibited the interaction 
of CyaA with cells by blocking anionic sites on the membrane. It is possible that these 
anionic sites correspond to membrane gangliosides which are negatively charged. In 
accordance with the glycolipid type of receptor (Eidels et al, 1983) CyaA does not 
enter cells by receptor mediated endocytosis (Gordon et a l , 1988; Donovan and Storm,
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1991). Nevertheless, the interaction of CyaA and other RTX toxins with target cells is 
an area which requires further research.
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OBJECTIVES OF RESEARCH
Bordetella pertussis produces an array of virulence factors which have been 
implicated in the pathogenesis of whooping cough. One such factor is adenylate cyclase 
toxin (CyaA), a unique bifunctional protein which possesses invasive adenylate cyclase 
and haemolytic activities. The mechanisms by which CyaA interacts with target cells are 
not clearly understood. This study aimed to investigate the binding/association of CyaA 
with eukaryotic cells, to understand the initial steps in the interaction of the toxin with 
cell membranes. CyaA exhibits broad cell specificity in terms of its toxic (invasive 
adenylate cyclase) and lytic activities. The study also aimed to investigate the specificity 
of CyaA by indentifying putative cell-surface receptor molecules.
CyaA is a member of the RTX family of genetically, functionally and 
immunologically related toxins. In common with other RTX toxins, CyaA is 
synthesised as an inactive precursor and is activated post-transiationally. This study 
also aimed to investigate the role that activation plays in the binding of CyaA to target 
cells and its contribution towards subsequent pore formation in cells and model 
membranes.
SEC TIO N  2 
M A TER IA LS AND M ETHO DS
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2.1 ORGANISMS
2.1.1 B. pertussis
The Bordetella pertussis strains used in this study were obtained from the 
culture collection of the Laboratory of Microbiology, University of Glasgow (Table 
2.1). B.pertussis 348 (pRMBl) was derived from B.pertussis 348, which carried a 
Tn5 insertion in the adenylate cyclase {cya A) gene (see section 1.4,2,1) and 
expressed no detectable enzymic or toxic activity (Glaser et al., 1988). In B.pertussis 
348 (pRMBl) the insertion mutation of B.pertussis 348 was complemented by 
pRMBl, a recombinant plasmid which contained the entire cya locus (Brownlie et al, 
1988). B.pertussis 348 (pRMBl) had elevated expression of enzymic and toxic 
activities and was therefore useful in this study.
B.pertussis DE386 contained an oligonucleotide insertion which inactivated 
the cyaC gene product, but did not affect expression of the structural gene, cyaA. 
This strain produced full length protoxin which has adenylate cyclase enzymic 
activity, but was non-invasive for S49-lymphoma cells (Barry et a l , 1991).
2.1.2 E.coli
Adenylate cyclase toxin (CyaA) was synthesized in the host strain E.coli 
DH5aF'IQ which had been transformed with DNA from the recombinant plasmids 
pCACT-3, pDLACT-1 and pICNOH (Figure 2.1). This plasmid expression system 
had been described previously (Betsou et al, 1993). Plasmid pCACT-3 encoded cya 
A, the structural gene for adenylate cyclase toxin., and also cya C, the gene involved 
in toxin activation (see section 1.4.2.2). Therefore, E.coli DH5aFIQ harbouring this 
plasmid produced activated CyaA. When E.coli DH5aF'IQ was transformed with 
pDLACT-1, which encoded cya A  alone, the non-activated form of CyaA was 
synthesized (Table 2.2). The host strain was also transformed with pICNOH, the 
vector for the cya inserts, as a control. The host E.coli strain and the plasmid DNA
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Table 2.1 B .pertussis  strains used in this study
Strain Relevant genotype
B.pertussis 348 (pRMBl) cyaA + cyaC
B.pertussis DE 348 cyaA
2.2 Recombinant E. coli strains used in this study
Strain Relevant genotype
E.coli DH5aFIQ
pDLACTl cyaA
pCACT3 cya A + cya C
pIClOH _
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Figure 2.1 Representation o f the plasm id system fo r  expression o f  
cya A and cya C genes in E.coli
Adapted from Betsou etal (1993)
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were kindly supplied by Dr Gareth Westrop (Division of Infection and Immunity, 
University of Glasgow).
2.2 PURIFICATION OF ADENYLATE CYCLASE TOXIN
2.2.1 Purification of adenylate cyclase toxin from B.pertussis
2.2.1.1 Growth conditions
B.pertussis was grown on Bordet Gengou (BG) medium (Gibco-BRL) 
containing 20% defibrinated horse blood, for 72h at 37°C in a humid atmosphere. 
Bacteria harvested from 2 lawn plates were inoculated into IL of cyclodextrin (CD) 
medium (Appendix 1), in 2L dimpled flasks. B.pertussis 348 (pRMBl) was grown in 
the presence of tetracycline (10 p,g/ml) and kanamycin (20 pg/ml). The flasks were 
incubated on an orbital shaker at 150 r.p.m. for 48h at 37°C. Cells were harvested by 
centrifugation at 9,000 x g for 30 min at 4®C (Sorval RC5B) and stored at -20^C.
2.2.1.2 Production of urea extracts
Cell pellets (4 grams wet weight) were resuspended in 82 ml of lOmM Tricine 
HCl, O.SmM EDTA, 0.5mM EGTA, pH 8.0 (Buffer A) containing 4M urea and ImM 
phenylmethylsulphonyl fluoride (PMSF). Suspensions were stirred for Ih at 4°C 
before centrifugation at 15,000 x g for 30 min at 4°C. The supernate was cleared by 
ultracentrifugation at 160,000 x g for Ih at 4®C and the resulting crude urea extracts 
stored at -20°C.
2.2.1.3 Calmodulin-agarose affinity chromatography
The urea extracts were diluted with an equal volume of Buffer A containing 
5mM CaCl2  to give a final urea concentration of 2M. The extracts were then mixed 
with 10ml of packed calmodulin agarose (Sigma) as described by Westrop et al
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(1994). This slurry was mixed gently for 2h at 4*^ C. After loading on a column 
(Econocolumn, 10 x 2.5 cm), the agarose was washed with 3 bed volumes (30ml) of 
lOmM Tricine HCl, ImM CaCl2 , 0.5M NaCl, pH 8.0 (Buffer B) followed by 30ml of 
Buffer A. Adenylate cyclase was then eluted with 30ml of Buffer A containing 8M 
urea. Purified urea extracts were stored at -70°C . The extracts were analysed by 
SDS-PAGE and Western Blotting (sections 2.6 and 2.7, respectively).
2.2.2 Purification of recombinant adenylate cyclase from E.coli
2.2.2.1 Transformation of competent cells with plasmid DNA
2.2.2.1.1 Production of competent cells
Host strain DH5a FTQ was grown on 2 x Yeast Tryptone (2YT) agar 
(Appendix 2) containing kanamycin (50 |ig/ml) for 16h at 37°C. An isolated colony 
was used to inoculate 10 ml of 2YT broth containing kanamycin (50 p,g/ml). The 
flasks were incubated on an orbital shaker (150 rpm), overnight at 37°C. This 
overnight culture (0.5 ml) was used to inoculate 50 ml of 2YT broth containing 
kanamycin (50 jxg/ml). The bacteria were grown on an orbital shaker (150 r.p.m) at 
37°C, to exponential phase (ODôsonm = 0.5-0.6 ). Competent cells were prepared by 
the method of Chung and Miller (1988). The cells were pelleted by centrifugation at 
1,000 X g for 10 min at 4°C (Sorval RC5B) and resuspended in 5 ml of 
Transformation storage buffer (TSB), (2YT broth containing 10% polyethylene 
glycol (Molecular weight 3,350), lOmM MgCl2 , lOmM MgSO^ and 5% DMSO) and 
kept on ice for 10 min. The competent cells were stored at - 70°C until required.
2.2.2.1.2 Transformation of competent cells
Competent cells (lOOpl) and 2 pi of plasmid DNA (pDLACT-1, pCACT-3 or 
pIC20H) were mixed in 1.5 ml microfuge tubes and incubated on ice for 5 min. To 
these mixtures 900 pi of TSB, containing 2mM glucose, was added. The
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transformation mixtures were then transferred to 20 ml universals and incubated for 
60 min at 37°C. Transformation mixtures (100 pi) were spread on 2YT agar 
containing kanamycin (50 pg/ml) and ampicillin (100 pg/ml). These plates were 
incubated overnight at 37^C to give isolated colonies which were stable for 2-3 days.
2.2.2.2 Production of E.coli extracts from transformed ceils
2.2.2.2.1 Growth conditions
Single colonies of the transformants were inoculated onto 2YT agar 
containing kanamycin (50 pg/ml) and ampicillin (100 pg/ml) and incubated overnight 
at 37°C to generate lawn plates. The lawn cultures were resuspended in 1ml of 2YT 
broth. The suspensions were then inoculated into 250 ml of 2YT broth containing 
kanamycin (50 pg/ml) and ampicillin (lOOpg/ml), at a starting ODôsonm of 0.01-0.02 
. The cultures were incubated on an orbital shaker (130rpm) at 37°C. Samples were 
taken hourly and the OD^^onm determined. At an ODgsonm of 0.3-0.4 the cells were 
induced with isopropyl-p-D-thiogalactopyranoside (IPTG) at a final concentration of 
ImM, and grown for a further 4h. To analyse expression of recombinant proteins 1ml 
samples were taken every hour and the cells harvested by centrifugation at 12,000 x g 
for 1 min at 4°C in a microfuge (Heraeus). The pellets were analysed by SDS-PAGE.
The cells were harvested by centrifugation at 9,000 x g for 10 min, at 4°C 
(Sorval RC5B) and pellets stored at -20°C.
2.2.2.2.2 Preparation of urea extracts
The harvested cell pellets were resuspended in 9 ml of 50mM Tris-HCl, 
lOmM EGTA and 20% sucrose (Buffer C). The cell suspension was then frozen in 
liquid nitrogen and thawed at 37®C. The cells were incubated in the presence of 1 ml 
lysozyme (lOmg/ml) for 15 min at 4°C and then lysed by 2 cycles of freezing in 
liquid nitrogen and thawing at 37°C. To the lysed cells, MgCl2  was added to a final
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concentration of 20mM, and DNase 1 (prepared in 150mM NaCl) was added to a 
final concentration of 20 kunitz units /ml. The lysates were incubated at 37°C until 
they were no longer viscous, whereupon 20 ml of Buffer C was added. Insoluble 
protein was harvested by centrifugation at 17,000 x g for 10 min at 4°C and the 
supernate (soluble protein fraction) was stored at -20°C .The pellet was resuspended 
in 3 ml of 50mM Tris-HCl, O.SmM EGTA, O.SmM EDTA containing 8M urea and 
the proteins were extracted by rotation at 4°C for 2h. The extract was transferred to
1.5 ml microfuge tubes and cleared by centrifugation at 15,000 x g for 20 min at 4°C. 
The supernate (urea extract) and the pellet (urea insoluble fraction) were stored at 
-20°C. Samples of the soluble protein fraction, urea extract and the urea insoluble 
fraction were examined by SDS-PAGE (secton 2.6).
2.2.2.3 DIALYSIS OF EXTRACTS
Immediately before assays were carried out, urea was removed from extracts 
of adenylate cyclase by dialysis against the appropriate assay buffer. The extracts 
were dialysed in a dialysis membrane (size 1-8/32") against 500 volumes of the 
appropriate assay buffer for 2 x Ih at 4°C with continuous stirring.
2.3 PROTEIN ESTIMATION OF SAMPLES
Protein concentrations were determined by the Bicinchinconic acid method of 
Smith et al (1985). Bovine serum albumin was used to generate a standard curve, 
from which the concentration of unknown samples was estimated.
2.4 ADENYLATE CYCLASE ENZYMIC ASSAY
The enzymic activities of the adenylate cyclase (Cya A) extracts were 
determined by the method of Salomon et al (1974). The assay measured the 
conversion of ( a^^P ) ATP to (^^P) cAMP. Enzymic activity was determined at 30°C
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in lOOjil of 25mM Tris-HCl, lOmM MgCh, pH 7.5 containing IjxM Bovine-brain 
Calmodulin (Sigma), and ImM ATP with 10  ^ cpm [a-^^P] ATP (Amersham). 
Reactions were terminated after incubation for 10 min by the addition of 100 pi of a 
solution containing 1% SDS, 20mM ATP and 6.25mM cAMP and immediately 
transferred to an iced-water bath.
The substrate [( a^^P ] ATP] and product of the reaction [(32p) cAMP)] were 
then separated by a double chromatography method using a Dowex 50 x 4 (200-400 
mesh) column and a Neutral alumina column. The Dowex column bound cAMP non- 
specifically and the majority of the labelled components were washed through. The 
bound cAMP and any remaining unreacted ATP were then washed onto the second 
column with distilled water. Bound cAMP was recovered from the column by 
washing with O.SmM imidazole, pH 7.4 and quantified by liquid scintillation 
counting.
2.5 ADENYLATE CYCLASE SHAPE-CHANGE ASSAY
The shape-change assay is a toxicity assay based on the principle that agents 
which increase intracellular cAMP levels inside BHK cells cause a change in the 
shape of the cells, called stellation. Stellated cells have a decreased ratio of area to 
perimeter when compared to normal cells, and this ratio can be used as a measure of 
the toxicity of particular agents.
2.5.1 Tissue culture and preparation of cells
The cells spreading assay was performed according to the method of Westrop 
et al (1994). BHK 21 cells were grown to 60% confluence in Glasgow-modified 
MEM medium (Macpherson and Stoker, 1962; House, 1964) buffered with 22mM 
HEPES, pH 7.4. and supplemented with 2% calf serum. Assays were performed in 
Hank's HEPES (HH) buffer pH 7.4, containing 140mM NaCl, 5.4mM HCl, 1.27mM
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MgCl2 , 1.3mM CaCl2 , 5.6mM D-glucose and lOmM HEPES pH 7.4. Monolayers 
were washed in Hanks Saline (Hanks HEPES without divalent cations) and cells 
removed from culture surfaces by the low trypsin-EDTA method (Edwards et a l , 
1975). Cells were aspirated in growth medium and washed twice by centrifugation 
and resuspension in Hanks saline. This procedure produced a planktonic suspension 
without affecting the rate of attachment and spreading on fibronectin-coated surfaces.
2.5.2 Shape-change assay
Bovine plasma fibronectin which had been purified from calf serum was 
kindly donated by Dr. Gareth Westrop (Division of Infection and Immunity, 
University of Glasgow). Cell spreading assays were performed in 24-well plastic 
tissue-culture plates. Wells were coated with 0.5 ml of fibronectin (25pg/ml) in HH 
for 15 min. This coating solution was replaced with 0.5 ml of HH containing 
0.5mg/ml haemoglobin, (to block free adsoiption sites) and the plates were incubated 
for a further 15min, before rinsing with HH. Cells (10^) in trypsinised suspension 
were mixed with dialysed CyaA extracts in 0.5 ml (final volume) of HH, and added 
directly to coated wells. Negative and positive controls were set up by mixing cells 
with HH and HH containing ImM dibutyryl cAMP, O.IM 3-isobutyl-l- 
methylxanthine (IBMX), respectively. After incubation for 90 min at 37°C, cells were 
fixed for 15 min by addition of 0.25 ml of 4% formaldehyde in phosphate-buffered 
saline, pH 7.2 . Cells were stained with Kenacid blue (0.1% in water : methanol : 
acetic acid , 50:50:7 by volume), rinsed twice in water and mounted in Gurr's 
Clearmount.
2.5.3 Image analysis
Images were obtained with the 40X objective on a Leitz Diavert microscope 
equipped with a Hamamatsu Vidicon C l000 camera and were digitized to 512 x256
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pixels and 64 grey shades using an Archimedes digitizer. Analysis was carried out 
with a programme written on Acorn Rise Machine Language for an Acorn 
Archimedes 310 microcomputer (Edwards et al, 1993). The programme measured cell 
perimeter and area and calculated the parameter dispersion as described by Dunn and 
Brown (1986). Dispersion was a measure of how much the cell shape differed from a 
circle. Stellation was accompanied by a decrease in the ratio of area to perimeter. The 
percentage of stellation caused by particular extracts was calculated by the following 
equation.
Stellation (%). = areaZperimeter(HH)^ - area/perimeter (extract) x 100
area/perimeter (HH) - area/perimeter (positive control)^
 ^buffer control
^HH containing ImM dibutyryl cAMP, O.IM IBMX
2.6 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)
SDS-PAGE was performed according to the method of Laemmli (1970) on
1.5 mm thick SDS-polyacrylamide gels using a vertical-slab gel tank. The stock 
solutions and recipes for gel and buffer preparation are shown in Appendix 2. The 
stacking gels and resolving gels contained 4.5% (w/v) and 7.5% (w/v) acrylamide, 
respectively. Samples were solubilised in an equal volume of solubilising buffer and 
boiled in a water bath at 100°C for 3 min. To estimate the molecular weight of 
proteins in samples, SDS-6H molecular weight standards (Sigma) were run on all 
gels. Samples were electrophoresed through the stacking gel and separating gels at 
20mA and 25mA respectively, until the tracking dye reached the bottom of the gel. 
Gels were stained either by the Coomassie blue staining method of Weber and 
Osborne (1969), or by the Silver staining method of Oakley et al (1980).
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2.7 WESTERN BLOTTING.
Protein transfer from SDS-PAGE gels onto nitrocellulose membranes 
(Hybond C, Amersham) was carried out according to the method of Towbin et al 
(1979). Protein transfer was carried out in a BioRad trans blot cell. The transfer buffer 
consisted of 20mM Tris, 150mM glycine (pH 8.0) and 20% methanol. Proteins were 
transferred at 130mA / 50V for Ihr, 80mA / 30V overnight and then 130mA / 50V 
for 30min.
After transfer the proteins were temporarily stained with Ponceau S solution 
(0.5% Ponseau S, in 1% acetic acid in distilled water) for 3 min, followed by washing 
in distilled water for 2 min. The positions of molecular weight markers were marked 
on the membranes before completely destaining in PBS. The membranes were 
immersed in blocking buffer (3% powdered milk, 0.2% Tween-20 in PBS), and 
gently shaken for Ih at room temperature and then washed for 3 x 10 min in PBS. 
Blots were then probed with monospecific anti-CyaA (1/1000 dilution in blocking 
buffer) on a rocking platform for Ih at room temperature, followed by washing as 
described above. The membranes were then probed with HRP-labelled anti-rabbit IgG 
(SAPU, 1/1000 dilution in blocking buffer, with shaking for Ih at room temperature. 
The nitrocellulose membrane was washed, then developed with DAB developer 
[containing 0.05% w/v 3-3 diaminobenzidine tetrahydrochloride (DAB), 98ml PBS, 
2ml C0 CI2  (1%), and lOOpl H2 O2  (30%)]. When the desired staining was achieved 
the reaction was stopped with distilled water. The membranes were then dried and 
stored in the dark.
2.8 PREPARATION OF ANTISERUM AGAINST ADENYLATE CYCLASE 
TOXIN
Unconcentrated monospecific anti-adenylate cyclase (anti-CyaA) serum was 
kindly supplied by Dr Yasmeen Kazi (Division of Infection and Immunity, University
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of Glasgow). The antiserum was raised against calmodulin-agarose chromatography 
purified CyaA from B.pertussis 348 (pRMBl). The antiserum had been prepared by 
inoculating a New Zealand Albino rabbit with sonicated nitrocellulose containing 
CyaA (Dr Yasmeen Kazi, PhD Thesis, University of Glasgow, 1992).
2.8.1 Concentration of antiserum by saiting-out
Unconcentrated anti-CyaA serum (50 ml) was mixed with 35 ml, 100% 
saturated ammonium sulphate, stirred for Ih at room temperature and then centrifuged 
at 6,000 X g for 10 min at 4®C (Sorval RC5B). The pellet was resuspended in 35 ml 
of 100% ammonium sulphate and stirred for 30 min at room temperature. This 
suspension was centrifuged again at 6,000 x g for 10 min at 4°C (Sorval RC5B) and 
the pellet resuspended in 10ml of 0.15 M NaCl. To remove the ammonium sulphate 
the suspension was dialysed for 2 x 2h, then overnight, at 4°C against 500 volumes 
of 0.15 M NaCl. The concentrated immunoglobulin was stored at -20°C until future 
use.
2.9 PREPARATION OF CELLS FOR ASSAYS
2.9.1 Isolation of sheep red blood cells
Defibrinated Sheep blood (5ml) was gently layered onto 10 ml Ficoll-Paque 
(Pharmacia) in 15ml conical centrifuge tube and centrifuged at 2,000 x g for 10 min 
(Medifuge). The supernate was discarded and the pellet resuspended in 15 ml of Tris 
buffered saline containing 2mM CaCl% (TBSC). The suspension was centrifuged 
again at 2,000 x g for 10 min, and the pellet washed a further 2-3 times until the 
supernate was clear. Finally the red blood cells (RBCs) were resuspended in 5ml 
TBSC. The cells were counted in an Improved Neubauer counting chamber and 
diluted to the appropriate concentration in the appropriate assay buffer.
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2.9.2 Preparation of Baby Hamster Kidney (BHK) cells
Cells were grown and isolated by trypsinisation of monolayers as described in 
section 2.5.1. An aliquot (50pl) of the trypsinised cells was removed, stained with 
Trypan blue (50 pi), and the live cells were counted in a counting chamber. Cells 
were centrifuged at 5,000 x g for 10 min (Medifuge) and resuspended in HH to 10^ 
cells/ml for use in cell binding assays.
2.9.3 Preparation of Bovine Lymphoma (BL3) cells
Cells were maintained in RPMI 1640 Medium (Gibco) containing 20% foetal 
calf serum and 2.5mM L-glutamine at between 1.0 x 10  ^and 1.0 xlO^ cells/ml in 25 
cm^ tissue culture flasks. Cells were gently resuspended and a sample removed and 
stained with Trypan blue before live cells were counted as above. Cells were 
centrifuged at 5,000 x g for 10 min (Medifuge) and resuspended in HH to 10^ 
cells/ml for use in cell binding assays.
2.9.4 Preparation of murine macrophage cell line (J774.2)
Cells were maintained in RPMI 1640 Medium(Gibco) containing 10%.foetal 
calf serum, 2.5mM L-glutamine and amphoterocin B (2.5 pg/ml) at between 1.0 x 
10  ^ and 1.0 X10  ^cells/ml in 25 cm^ tissue culture flasks. The cells were stained and 
counted as above. Cells were centrifuged at 5,000 x g for 10 min (Medifuge) and 
re suspended in HH to 10  ^cells/ml for use in cell binding assays.
2.10 CELL BINDING ASSAY
The cell binding assay was based on the method of Rogel and Hanksi (1991). 
Binding of CyaA to sheep RBCs, BHK cells, BL3 cells and J774.2 cells was 
investigated. The cells were isolated as described above and resuspended in HH
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containing 2mM CaCl2  (unless otherwise stated). The RBCs (2x 10  ^cells/assay) or 
BHK, BL3 and J774.2 cells (5 x 10  ^ cells/assay) were incubated with dialysed 
extracts in 1ml (final volume) for 60 min at 37°C, unless otherwise stated. The 
mixture was then centrifuged at 12,000 x g for 5 min. The cell pellet was 
resuspended in lOmM Tris-HCl, 2mM MgCla, 1mm EDTA, pH 7.4 (TME buffer.) 
and cells lysed by 2 cycles of freezing in liquid nitrogen and thawing to 37°C. The 
membrane pellets were washed a further three times in TME and finally resuspended 
in 100 pi of TME. Membrane proteins (50pl) were then separated by SDS-PAGE 
and transferred to nitrocellulose by Western blotting, before probing with 
monospecific anti-CyaA serum for the presence of CyaA in the membrane fraction 
(section 2.7).
2,10.1 Binding assay using trypsinised erythrocytes
Sheep RBCs were isolated as above, resuspended to 2 x 10  ^ cells/ml and 
treated with trypsin (25-lOOpg/ml), prepared in HH, for 60 min at 37°C. Cells were 
then centrifuged at 12,000 x g for 5 min and resuspended in 1ml of HH. To remove 
the trypsin the cells were then washed in HH a further 4 times. The binding assay was 
then carried out as above.
2.11 NITROCELLULOSE OVERLAY ASSAY
This procedure was developed to isolate protein receptors for CyaA and was a 
variation of a method previously described by Knowles and Ellar (1986). Membrane 
proteins from sheep erythrocytes were separated by SDS-PAGE, transferred to 
nitrocellulose and overlaid with CyaA. Binding of CyaA to the proteins was detected 
by use of labelled anti-CyaA antibodies.
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2.11.1 Preparation of nitrocellulose for overlay
Sheep erythrocytes membranes were prepared as described in section 2.9.1.1. 
The membranes containing 5-10 pg protein, were separated by SDS-PAGE and either 
stained by the Silver staining method of Oakley et al (1980), or transferred to 
nitrocellulose by Western blotting (Towbin et al, 1979). The nitrocellulose was 
immersed in blocking buffer (3% powdered milk, 0.2% Tween-20 in TBS containing 
2mM CaCl2  (TBSC)) and gently shaken for Ih at room temperature.
2.11.2 Overlay of nitrocellulose with adenylate cyclase toxin
The blocked nitrocellulose was overlaid with 50 pg/ml CyaA purified from 
BP348 (pRMBl) in blocking buffer, overnight at 4°C unless otherwise stated. The 
membrane was washed for 3 x 10 min in blocking buffer before probing with 
monospecific anti-CyaA serum (1/1000 dilution in Blocking buffer) with shaking for 
Ih at room temperature, followed by washing as described above. Two procedures 
were then tested to detect the binding of CyaA to the sheep RBC membrane proteins 
and are described below in sections 2.11.3 and.2.11.4 and in Figure 2.2.
2.11.3 Immunodetection
In this procedure the nitrocellulose was further overlaid with HRP-labelled 
anti-rabbit IgG (SAPU, 1/1000 dilution in blocking buffer), and shaken for Ih at room 
temperature, washed and then developed with DAB developer solution as described 
in section 2.7.
2.11.4 Radioisotope-detection
In this procedure the nitrocellulose was further overlaid with biotinylated anti­
rabbit IgG (Amersham), (1/400 dilution in blocking buffer) for Ih at room
Section 2 54 Materials and Methods
Figure 2.2 Overlay assays to detect binding o f CyaA to membrane proteins
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temperature. The nitrocellulose was then washed in blocking buffer and overlaid with 
5pCi I25x-streptavidin (Amersham) for Ih at room temperature. Unbound isotope 
was removed by washing (6 x lOmin) in blocking buffer and the nitrocellulose was 
then exposed for 3-5 days to blue sensitive X-ray film (Genetic Research 
Instrumentation Ltd) with intensifying screens at 70°C.
2.12 THIN-LAYER CHROMATOGRAM ASSAY
2.12.1 Preparation of glycolipids
Sheep RBCs were isolated from fresh whole blood as described in Section 
2.9.1.1. From 60 ml of defibrinated sheep blood, 30 ml of 50% volume RBCs were 
prepared. Glycolipids were isolated from RBCs by a method adapted from that of 
Saito and Hakamori (1971). Bovine brain gangliosides were obtained from 
Calbiochem, and consisted of a mixture of the gangliosides GM%, GDia, GDib, and 
GTib.
RBCs were homogenised with 20 volumes (600ml) of chloroform: methanol 
(2:1) with a mortar and pestle. The homogenate was filtered through a Buchner funnel 
using 7.5 cm charcoal filter paper. The filter paper and retentate were re-extracted 
with 10 volumes (100ml) of chloroform: methanol (1:2) + 3% H2 O and then filtered 
through a Buchner funnel. The combined filtrates were refiltered, shell dried in a 
rotary evaporator, and weighed. The yield of this procedure ranged from 200-500 mg. 
The lipid was resuspended in chloroform : methanol (2:1), filtered and stored at 
-20»C.
2.12.2 Chromatogram overlay assays
Glycolipids were chromatographed on aluminium-backed silica gel thin-layer 
plates (Merck LTD), which had been prebaked for 30 min at lOO^C. The 
chromatograms were developed with chloroform:methanol : KCl (0.1%) [5: 4: 1, by
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vol.] unless otherwise stated. To visualise the lipids the plates were stained with 
resorcinol reagent (Appendix 4). Unstained chromatograms were run in parallel for 
use in overlay assays.
Binding of CyaA to glycolipids separated on these chromatograms was 
investigated by a method adapted from that of Magnani et al (1980). Chromatograms 
were dipped into a solution of poly-isobutylmethacrylate (0.1%) in hexane, air dried 
and incubated in blocking buffer (3% powdered milk in TBS containing 2mM 
CaCli). The blocked chromatograms were then overlaid with 50p,g/ml CyaA purified 
from BP348 (pRMBl), incubated overnight at room temperature (unless otherwise 
stated), and then washed (3x 10 min) with blocking buffer. The chromatograms were 
probed with monospecific anti-CyaA serum (1/1000 dilution in blocking buffer) with 
shaking for Ih at room temperature, followed by washing as described above. Two 
procedures were then tested to detect the binding of CyaA to the separated lipids as 
described below in sections 2.12.2.1 and 2.12.2.2 and in Figure 2.3.
2.12.2.1 Immunodetection
Chromatograms were overlaid with HRP-labelled anti-rabbit IgG (SAPU, 
1/1000 dilution in blocking buffer), shaken for Ih at oom temperature, washed and 
then developed with a DAB developer solution (section 2.7).
2.12.2.2 Radioisotope- detection
Chromatograms were overlaid with biotinylated anti-rabbit IgG (Amersham) 
(1/400 dilution in blocking buffer) for Ih at room temperature, washed in blocking 
buffer and overlaid with 5pCi of ^^^I-streptavidin (Amersham) for Ih at room 
temperature. Unbound isotope was removed by washing (6x lOmin) with distilled 
water and the chromatogram was exposed for 3-5 days to blue sensitive X-ray film 
(Genetic Research Instrumentation Ltd) with intensifying screens at 70°C.
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Figure 2.3 Overlay assays to detect binding of CyaA to membrane lipids
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2.13 HAEMOLYSIS ASSAY
The haemolytic activity of native and recombinant Cya A was determined by 
a microtitre assay adapted from Hewlett et al, (1993). Sheep erythrocytes (sRBCs) 
were isolated from whole blood as described earlier (section 2.9.1.1), and diluted in 
haemolysis assay buffer (PBS cintaining 2mM CaCl2 ). Haemolysis was measured 
after mixing sRBCs (10^ cells) with dialysed extracts in 100 jil (final volume) and 
incubation for 3h at 37°C, unless otherwise stated. Reactions were also set up to 
measure any haemolysis induced by the appropriate buffers. Reactions were stopped 
by the addition of 150 |il of ice cold PBS to each well. From each well, 200 pi 
samples were removed and centrifuged at 2,000 x g for 10 min at 4°C (Biofuge). The 
supernatants (lOOpl) were then transferred to a fresh microtitre plate and OD 540nm 
was determined in a spectrophotometer (Anthos Labtech instruments).
The background and 100% haemolysis values were determined by incubating 
sRBCs (10^ cells) with haemolysis assay buffer and 1% saponin (final concentration), 
respectively, in an identical assay system. The haemolytic activity of extracts was 
determined by the following equation:
Haemolysis (%) = OD 540nm (extract) - OD 540nm (background) x 100
OD 540nm (saponin)
2.14 LIPOSOME ASSAY
2.14.1 Preparation of liposomes by cross-flow dialysis
Liposomes were prepared by cross flow dialysis of mixed micelles in an 
adaptation of methods described by Milsmann et al (1978) and Brunner et al (1976). 
The lipids used in the preparation of liposomes by this method,
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distearoylphosphatidylcholine (DSPC) and dicetyl phosphate (DCP), were purchased 
from Sigma.
The lipids DSPC :DCP (molar ratio 9:1) were dissolved in chloroform and 
dried in vacuo at 40®C using a rotary evaporator (Buchi). A mixed micelle solution 
was then prepared by combining the dried lipid with the detergent, sodium cholate 
(Sigma) in a molar ratio 0.62 : 1 (lipid: detergent). The fluorescent calcein buffer (6 
ml of 80mM calcein (Sigma), 150mM NaCl, 2mM CaCh, 0.5mM MgCl2 , pH 8.0) 
was then added. Liposomes encapsulating the fluorescent marker were prepared by 
removal of the detergent from the lipid by cross-flow dialysis through dialysis 
membranes (molecular weight cut off, 10,000 kDa) against 150mM NaCl, 2mM 
CaCl2 , 0.5mM MgCl2 , pH 8.0 using a Liposomat liposome maker (Dianorm). Flow 
rate was set at between 1 ml and 2 ml/min.
2.14.2 Preparation of liposomes by freeze-tbawing and cbromatograpby
The lipids used in the preparation of liposomes were dimyristoyl phosphatidyl 
choline (DMPC), cholesterol (C), dicetyl phosphate (DCP), stearylamine (SA), and 
trisialoganglioside (GTib ) and were purchased from Sigma. Different combinations 
of these lipids were used to alter the charge and composition of liposomes. 
Liposomes were prepared from DMPC : C : x (molar ration of 1.0 : 0.75 : 0.03) 
where x was either DCP, SA or GTib, by adaptation of the method of Pick et al 
(1981).
Lipids were dissolved in chloroform, mixed in appropriate combinations 
(12.9p.mol lipid in total) and dried in vacuo at 40°C using a rotary evaporator 
(Buchi). The dried lipid was emulsified in 3ml of calcein buffer (80mM calcein. 
Sigma, 150mM NaCl, 2mM CaCh, 0.5mM MgCh, pH 8.0) by sonication in a bath 
sonicator (Ultrasonics Ltd) for 2-3 min. The emulsion was then incubated for 90min 
at 37°C to allow the liposomes to swell. The multilamellar vesicles were observed
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under phase contrast microscopy and then broken down to small unilamellar vesicles 
by sonication for 4 x Imin with a probe sonicator (Soniprep-150) at constant 
temperature.
Large unilamellar vesicles were prepared by 2 cycles of freezing multi­
lamellar vesicles in liquid nitrogen and thawing at 37°C. The vesicles were 
equilibrated by incubation at 37°C for 90 min. To remove unsequestered calcein, the 
liposomes were passed twice through a Sephadex G-50 column (10 x 1.5 cm), and 
eluted with 50mM NaCl, 2mM CaCl2 , 0.5mM MgCh, pH 8.0) (Liposome assay 
buffer).
2.14.3 Pore formation assay
Release of the fluorescent marker (calcein) from liposomes was measured at 
room temperature using a fluorescence spectrophotometer (Cytofluor 2300). 
Excitation and emission were set at 485 nm and 530 nm respectively. Assays were 
carried out by mixing liposomes (50 pi) with the appropriate dialysed extracts in 
200pl (final volume) or dialysed extract buffer as a control. These assays were 
carried out in flat bottomed 96 well plates (Nunc 96) and fluorescence was measured 
for 300 min. Spontaneous release (background) was determined by measuring marker 
release from the liposomes in the Liposome assay buffer (200 pi final volume). Full 
marker release (100%) was determined by treating liposomes with 2% Triton-X 100 
(final concentration).
The activity of extracts on liposomes was determined by the following 
equation:
Activity (%) = Fluorescence (extract or buffer ) - Fluorescence (background) x 100
Fluorescence (Triton X-100)
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3.1 PURIFICATION AND CHARACTERISATION OF ADENYLATE 
CYCLASE TOXIN
3.1.1 Purification of adenylate cyclase toxin from B .p er tu ss is  348 
(pRMBl)
Adenylate cyclase toxin (CyaA) was prepared from B.pertussis 348 
(pRMB 1) by a two stage process involving an initial treatment of whole cells with urea, 
followed by purification of this urea extract by calmodulin-agarose (CaM)-affinity 
chromatography as described in section 2.2. Treatment of whole cells, from BP348 
(pRMBl), with urea resulted in the extraction of a number of polypeptides, including 
high levels of a protein with a molecular weight of approximately 200 kDa (Lane 1, 
Figure 3.1a). When the urea extract was subjected to CaM-affinity chromatography, 
the 200 kDa protein, which was believed to be CyaA, was purified (Lane 2, Figure 
3.1a). However, the chromatography step also resulted in the purification of a 60 kDa 
polypeptide (Lane 2, Figure 3.1a). This protein band was probably a degradation 
product of the full length adenylate cyclase toxin and corresponded to the catalytic 
domain of CyaA (see section 1.4.1.1). CyaA interacts with calmodulin, and this 
property was used in the purification process. The other components of the urea extract 
did not interact with the calmodulin and were collected in the flow through from the 
chromatography column (Lane 3, Figure 3.1a). Probing of an immunoblot with 
monospecific anti-CyaA serum confirmed that the 200 kDa protein purified by CaM- 
agarose chromatography, was CyaA (Lane 2, Figure 3.1b).
On a number of occasions attempts were made to purify CyaA from 
B.pertussis DE386, but the urea extract did not penetrate the calmodulin-agarose 
column.
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Figure 3.1a Purification o f  CyaA from  B.pertussis 348 (pRM Bl) - SDS- 
PAGE analysis. Crude urea extracts from B.pertussis 348 (pRMBl) were purified 
by CaM-agarose affinity chromatography. Samples (50jXg) were separated by SDS- 
PAGE and the gels were stained with Coomassie blue. Lane 1, crude urea extract of 
CyaA from B.pertussis 348 (pRMBl); Lane 2, affinity column purified CyaA from 
B.pertussis 348 (pRMBl); Lane 3, flow through from affinity column.
F igure 3.1b Purification o f  CyaA from  B .pertussis 348 (pR M B l)  - 
Western blot analysis. Crude urea and CaM-agarose affinity column purified 
extracts from B.pertussis 348 (pRMBl) which were run on SDS-PAGE, transferred to 
nitrocellulose and probed with monospecific anti-CyaA serum as described in section 
2.7. Lane 1, crude urea extract of CyaA from B.pertussis 348 (pRMBl); Lane 2, 
affinity column purified CyaA from B.pertussis 348 (pRMB 1).
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3.1.2 Purification of recombinant adenylate cyclase toxin from E.coli
Competent cells of E.coli DH5a F'lQ were transformed with DNA from the 
plasmids pCACT-3, pDLACT-1 and pIC20H (Figure 2.1). The recombinant plasmid 
genes were under control of the lac promoter and thus inducible with IPTG (Betsou et 
al, 1993). Growth of these strains was followed spectrophotometrically until mid­
exponential phase, when they were induced with IPTG (Figure 3.2). After induction, 
E.coli DH5a F’lQ (pCACT-3) and E.coli DH5a F'lQ (pDLACT-1) demonstrated a 
considerable increase in synthesis of a 200 kDa protein with time (Figure 3.3). The 
control strain [E.coli DH5aF’IQ (pICNOH)], harbouring the vector plasmid which did 
not contain cya inserts, did not synthesize this 200 kDa protein. Treatment of the cells 
from E.coli DH5a F'lQ (pCACT-3) and E.coli DH5a F'lQ (pDLACT-1) with urea 
resulted in the partial purification of the 200 kDa protein (Lane 4, Figure 3.4a). 
This protein was not purified from the control strain (Figure 3.4a). When the urea 
extracts from E.coli DH5a F'lQ (pCACT-3) (Lane 1) and E.coli DH5a F'lQ 
(pDLACT-1) (Lane 2) were analysed by Western Blotting, using monospecific anti- 
CyaA serum, the 200 kDa protein was identified as CyaA (Figure 3.4b).
3.1.3 Enzymic activity of adenylate cyclase toxin
To further characterise the extracts purified from B.pertussis and E.coli an 
adenylate cyclase enzymic assay was carried out as described in the section 2.4 
(Salomon et a l , 1974). The assay measured the conversion of (a^^P) ATP to (3^P) 
cAMP. The specific activities for the different extracts are shown in Table 3.1. These 
results demonstrated that catalytically active forms of CyaA had been purified from the 
recombinant E.coli strains and from B.pertussis 348 (pRMBl). The extracts tested 
had similar enzymic activities which were within a factor of two. These results revealed 
that both activated and non-activated forms of CyaA, were catalytically active. Thus, 
enzymic activity was not dependent upon toxin activation. The specific activities for the
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Figure 3.2 Purification o f  recombinant CyaA : Growth and induction  
o f recombinant E.coli strains, The E.coli strains were grown at 37®C until 
ODôsonm reached 0.3-0.4, whereupon the cells were induced with ImM IPTG and 
grown for a further 4h to express the recombinant proteins (see section 2.2.2), The 
strains grown were Vector = E.coli DH5aFTQ (pICNOH), pDLACT-1 -E .coli 
DH5aFTQ (pDLACT-1) and pCACT-3 = E.coli DH5aF'IQ (pCACT-3).
Section 3 65 Results
kDa 
205 —
116 —
97 —
66 —  
45 —
29 _
pCACT-3
1 2 3 4 5
pDLACT-1
1 2 3 4 5
pICNOH
1 2 3 4 5
« # # #  ma
Figure 3.3 Purification o f recombinant CyaA: Expression o f recombinant CyaA 
in E .coli. Host strain E.coli DHSaF'IQ harbouring either pCACT-3, pDLACT-1 
or pIC20H was induced with IPTG. Samples were taken at intervals from the three 
strains and 50 pi of these were separated by SDS-PAGE. Gels were stained with 
Coomassie blue. Lane 1, non induced cells; Lane 2, Ih after induction; Lane 3, 2h 
after induction; Lane 4, 3h after induction; Lane 5, 4h after induction.
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Figure 3.4a Purification o f  recom binant CyaA : Urea extraction o f  
recombinant E.coli strains. Recombinant proteins were expressed in E .coli 
DH5aF'IQ harbouring either pDLACT-1, pCACT-3 or pICNOH and extracted with 
urea as described in section 2.2.2. The proteins (50pg) were then separated by SDS- 
PAGE and the gels were stained with Coomassie blue. Lane 1, total cell protein; Lane 
2, soluble protein fraction; Lane 3, insoluble protein fraction; Lane 4, urea extract.
Figure 3.4b Purification o f  recombinant CyaA : Western Blot analysis.
Urea extracts of recombinant proteins were separated by SDS-PAGE, transferred to 
nitrocellulose by Western Blotting and probed with monospecific anti-Cya A serum as 
described in section 2.7. Lane 1, CyaA from E.coli DH5aF'IQ (pCACT-1); Lane 2, 
CyaA from E.coli DH5aF'IQ (pDLACT-1); Lane 3, extract from E.coli DHSaF'IQ 
(pICNOH).
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Table 3.1 Determination of adenylate cyclase enzymic activity of  CyaA 
extracts by the Salomon assay
Strain
Specific Activity  ^
Activation (pmol cAMP/min/mg protein)
B. pertussis 348 (pRMBl)^
E.coli (pGW22)d
activated
E.coli. DHSaF'IQ (pCACT-3)^ activated
E.coli DHSaF'IQ (pDLACTl)^ non-activated
non activated
32
42
34
26
^Mean of 3 determinations
t>CaM-agarose affinity chromatography purified extract 
^Urea extract
(^Donated by Dr Gareth Westrop, University of Glasgow
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recombinant CyaA proteins were slightly lower, but still similar to those achieved by 
other investigators (Westrop et al, 1986). It was decided to use the protein 
concentration of the extracts, as determined by the method of Smith et al (1985), to 
standardise them for future assays.
3.1.4 Toxic activity of adenylate cyclase toxin
To characterise the toxicity of extracts a Baby Hamster Kidney (BHK) cell 
shape change assay was carried out. The assay proved to be a rapid and sensitive assay 
for the invasive adenylate cyclase toxin (Westrop et al, 1994). The assay was based on 
the principal that increases of cAMP levels in BHK cells, induced by agents such as 
CyaA, resulted in altered cell morphology, called stellation. The degree of stellation 
was used as a measure of the toxicity of extracts (described in section 2.5). The shape 
change assay demonstrated that activated forms of CyaA purified from BP348 
(pRMBl) and E.Coli DH5aFIQ (pCACT-3) were toxic to BHK 21 cells. This 
toxicity was dose-dependent (Figure 3.5). Determination of the concentration of 
CyaA giving half-maximal stellation gave an indication of the relative toxicity of the 
extracts. For CyaA, purified from BP348 (pRMBl) and E.coli DH5aF'IQ (pCACT- 
3), half maximal stellation occurred at protein concentrations of 0.3 pg/ml, and 0.52 
pg/ml, respectively. The half maximal values for the extracts were similar to those 
found by Westrop et al (1994).
The non-activated form of CyaA purified from E.coli DH5aFTQ (pDLACT-1) 
was non-toxic (stellation < 5%) to BHK cells in the shape-change assay (Figure 3.5). 
These results indicated that activation of CyaA was important for toxicity and agreed 
with toxicity studies carried out on other cell types (Betsou et al, 1993; Hewlett et al, 
1993).
Section 3 69 Results
100 “1
80 -
60 -§
I pCACT-3
pRMBl
pDLACT-1
o40 -
20 -
100.01 . 1 101
Concentration of CyaA (jiLg/ml)
Figure 3.5 Stellation of BHK 21 cells by CyaA
Toxicity of dialysed extracts was measured by the BHK 21 shape change assay. Mean 
cell area and perimeter were determined by analysis of 25 cells for each treatment. For 
the purposes of experiments, 100% stellation was defined as stellation caused by HH 
containing ImM dibutyryl cAMP, 0.1 M IB MX, and test samples were compared to 
this value (Section 2.5). Bars represent the mean ± the S.E.M of 4 determinations from 
2 independent experiments.
pRMB 1 = CyaA purified from BP348 (pRMB 1) by affinity chromatography
pCACT-3 = Urea extract of activated CyaA from E.coli. DH5aF'IQ (pCACT-3)
pDLACT-1 = Urea extract of non-activated CyaA from E.coli. D H 5aFTQ  
(pDLACT-1)
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Figure 3.5a Stellation ofBHK21 cells (Source: Westrop et al, 1994).
BHK shape change assay was performed by the same method as described in this 
thesis (section 2.5). Plate A shows unstellated control BHK cells. Plate B shows 
cells after treatment with ImM disbutyryl cAMP and 0. IM IBMX. Similar results 
were obtained in this study when cells were treated with activated extracts of CyaA 
as described in Figure 3.5, but photographs were not available.
j
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3.2 BINDING OF ADENYLATE CYCLASE TOXIN TO CELLS
3.2.1 Binding to sheep erythrocytes
To investigate the interaction of CyaA with target cells a whole-cell binding 
assay was employed. The binding assay was based on the fact that when CyaA bound 
to cell membranes, and the cells were lysed, the CyaA-membrane complex could be 
separated from unbound toxin and target cell components by centrifugation. When the 
membrane pellet was washed, resolved by SDS-PAGE, and transferred to 
nitrocellulose by Western Blotting, CyaA could be detected by probing with 
monospecific anti-CyaA serum (Section 2.10).
^^ J^Before looking at the binding process in more detail it was necessary to 
demonstrate that CyaA would indeed bind to sheep erythrocytes, a convenient target 
cell system. As the incubation time of CyaA with sheep erythrocytes was increased 
there was an increase in the intensity of the 200 kDa CyaA protein band detected on an 
immunoblot from CyaA treated cells. The majority of CyaA was bound by 30 min 
(Lane 3) and increased only slightly after 60 min (Lane 4) and 120 min (Lane 5, 
Figure 3.6) as detected by the binding assay employed. Untreated erythrocytes did 
not show the presence of the 200 kDa protein band (Lane 2, Figure 3.6). When 
sheep erythrocytes were incubated with increasing concentrations of CyaA, there was a 
concomitant increase in the amount of toxin which was bound (Lanes 3-8, Figure
3.7). Binding could be detected when erythrocytes were incubated with as little as 5 
fig/ml of CyaA (Lane 7, Figure 3.7). These results demonstrated that CyaA bound 
to sheep erythrocytes in a time-dependent (Figure 3.6) and dose-dependent (Figure
3.7) manner.
Section 3 71 Results
—  200  k D a
F ig u re  3 .6  Effect o f incubation time on binding o f CyaA to sheep erythrocytes 
Sheep RBCs were incubated with dialysed CyaA (100 jLig/ml), purified from BP348 
(pRMBl). RBC membrane ghosts were prepared and resolved by SDS-PAGE. 
Bound toxin was detected by transferring membrane proteins to nitrocellulose and 
probing with anti-CyaA serum, as described in section 2.10. Lane 1, CyaA control 
(10 jig); Lane 2, untreated RBC control (10 jig); Lane 3, 4 and 5, RBCs incubated 
with CyaA for 30, 60, and 120 min, respectively.
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F ig u r e  3 .7  Effect o f concentration o f CyaA on its binding to sheep erythrocytes
Sheep RBCs were incubated with dialysed CyaA, purified from BP348 (pRMB 1 ), for
Ih at 37«C. RBC membrane ghosts were prepared and resolved by SDS-PAGE.
Bound toxin was detected by transferring membrane proteins to nitrocellulose and 
probing with anti-CyaA serum, as described in section 2.10.. Lane 1, CyaA control 
(10 |ig); Lane 2, untreated RBC control (10 pg); Lanes 3-8, RBCs incubated with
100, 50, 20, 10, 5 and 1 |ig/ml CyaA, respectively.
J
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3.2.2 Binding of adenylate cyclase to trypsinised sheep erythrocytes
There has been limited research into the specificity of the interaction of CyaA 
with target cells. Therefore, a study was carried out to determine if proteolytic treatment 
of sheep erythrocytes affected the subsequent binding of CyaA. Erythrocytes were 
treated with a range of concentrations of trypsin as described in section 2.10.1. 
Treatment of sheep erythroctes with trypsin altered the SDS-PAGE profile of the 
erythrocyte membrane proteins (Figure 3.8). As the concentration of trypsin was 
increased, there was a subsequent increase in cleavage of the membrane proteins 
demonstrated by loss of a number of the protein bands (Lanes 2-5, Figure 3.8). 
This indicated that trypsinisation of the erythrocytes altered their surface composition.
When CyaA was incubated with trypsinised erythrocytes the toxin was not 
detected in the membrane fraction of the cells. (Figure 3.9a). This occurred when 
cells were treated with as low as 25|ig/ml trypsin (Lane 3, Figure 3.9a). However, 
CyaA was detected in the membranes of the control cells (Lane 2) which were not 
trypsinised (Figure 3,9a). These results suggested that CyaA did not bind to 
trypsinised erythrocytes. In contrast, trypsinised erythrocytes were found to be more 
sensitive to haemolysis by CyaA. The haemolytic activity of CyaA was dependent upon 
the concentration of trypsin used to treat the erythrocytes.(Figure 3.9b).
Proteolytic degradation of CyaA, due to low levels of residual trypsin, may 
have resulted in the loss of binding of CyaA to trypsinised cells. To test this a binding 
assay was carried out in which a cocktail of protease inhibitors had been incorporated. 
Cells were treated with trypsin, washed as before, and then incubated with CyaA in the 
presence of PMSF (200jiM), leupeptin, (IfiM) and pepstatin (l|xM). The cocktail 
provided a broad range of protease protection (Boehringer-Mannhein, Biochemical 
Information Leaflet, May 1987). However, CyaA did not bind to trypsinised 
erythrocytes, when co-incubated with the protease inhibitors (Lanes 4-7, Figure 
3.10). This suggested that it was not degradation of CyaA by trypsin that prevented
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Figure 3.8 SDS-PAGE profile o f trypsinised erythrocytes membrane proteins.
Sheep RBCs were pretreated with trypsin (25-100 pg/ml) for 60 min at 3?oC. 
After washing the RBCs were lysed and the membranes proteins were separated 
by SDS-PAGE and stained with Silver stain as described in section 2.6. Lane 1, 
untreated RBC control (10 p.g); Lanes 2-5 RB's treated with 25, 50, 75 and 100 
jig/ml trypsin, respectively
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Figure 3.9a Binding o f  CyaA to trypsinised erythrocytes 
Trypsinised erythrocytes were incubated with 100 p.g/ml of dialysed CyaA, purified 
from BP348 (pRM Bl), for 60 min at 37°C. RBC membrane ghosts were prepared and 
resolved by SDS-PAGE. Bound toxin was detected by transferring membrane proteins 
to nitrocellulose and probing with anti-CyaA serum, as described in section 2.10. Lane 
1, CyaA control (10 jig) ; Lane 2, CyaA incubated with untreated RBCs; Lanes 3-6, 
CyaA incubated with RBCs pretrypsinised with 25, 50, 75 and 100 |Lig/ml trypsin 
respectively ; Lane 7 untreated RBCs.
Figure 3.9b Haemolysis o f trypsinised erythrocytes by CyaA 
Sheep RBCs were treated with a range of concentrations of trypsin. RBCs were 
washed and incubated with 100 |ig/ml of dialysed CyaA, purified from BP348 
(pRMBl), for 60 min at 37°C. Haemolysis of RBCs was measured as described in 
section 2.13.
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F ig u r e  3 .10  Binding o f CyaA to trypsinised sheep erythrocytes in the presence of 
protease inhibitors. Trypsinised RBCs were incubated with 100 |ig/ml of dialysed 
CyaA, purified from BP348 (pRMBl), along with a cocktail of protease inhibitors 
(see text) for 30min at 37oC. RBC membrane ghosts were prepared and resolved by 
SDS-PAGE. Bound toxin was detected by transferring membrane proteins to 
nitrocellulose and probing with anti-CyaA serum, as described in section 2.10. Lane 
1, CyaA control (lOjLig); Lane 2, RBC control; Lane 3, CyaA/ inhibitors incubated 
with untrypsinised RBCs; Lanes 4-7, CyaA/inhibitors incubated with RBCs pre­
trypsinised with 25, 50, 75 and 100 jig/ml trypsin, respectively.
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the 'binding' of the toxin The loss of binding was probably due to the alteration in 
surface architecture of membrane receptors brought about by the protease activity.
3.2.3 Role of carbohydrates in cell-binding of adenylate cyclase toxin
The majority of receptors for bacterial toxins are carbohydrates and many of 
these contain contain sialic acid (see section 1.6). It has been suggested that the 
mammalian cell receptor for CyaA may also be a carbohydrate and in particular a 
ganglioside (sialic acid containing glycolipid), (Gable et al, 1985; Gordon et a l , 1989). 
Therefore, the cell-binding assay was adapted to investigate if there was a carbohydrate 
involvement in the binding of CyaA to sheep erythrocytes. To test this a number of 
simple carbohydrates [D-galactose, D-glucose, D-mannose, D-maltose, D-fucose or N~ 
acetyl neuraminic acid (NANA)] were examined to see if they blocked binding of CyaA 
to the cells by competition with a receptor. When CyaA was incubated with sheep 
erythrocytes, in the presence of these carbohydrates separately, it was found that none 
of the sugars tested prevented the binding of CyaA (Lanes 4-9, Figure 3.11), 
when compared to the binding control (Lane 2, Figure 3.11). This result suggests 
that either the carbohydrate moieties tested may not play an essential role in the binding 
of CyaA to erythrocytes, or that the receptor for CyaA may be an oligosaccharide of 
specific structure, not matched by these simple sugar residues.
3.2.4 Role of activation of adenylate cyclase toxin in cell-binding
B.pertussis CyaA is the product of the structural gene cya A. A number of the 
properties of CyaA are dependent upon prior activation, which is mediated by the 
product of the cya C gene (see section 1.4.2.2). To investigate the role activation 
played in the binding of CyaA to sheep erythrocytes, activated and non-activated forms 
of CyaA were prepared. Erythrocytes were incubated with the same concentration of 
activated and non-activated forms of CyaA and the binding analysed by the binding
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F ig u r e  3 .11  Binding o f CyaA to sheep erythrocytes in the presence o f different 
sugars. Sheep RBCs were exposed to lOOpg/ml of dialysed CyaA, purified from 
BP348 (pRMBl) and either 50 mM galactose, glucose, mannose, maltose, fucose or 
N-acetyl neuraminic acid (NANA). RBC membrane ghosts were prepared and 
resolved by SDS-PAGE. Bound toxin was detected by transferring membrane 
proteins to nitrocellulose and probing with anti-CyaA serum, as described in section 
2.10. Lane 1, CyaA control (10 |ig); Lane 2, RBCs incubated with CyaA ; Lane 3, 
RBC control; Lane 4-9, RB's incubated with CyaA and. Lane 4, galactose; Lane 5, 
glucose; Lane 6; mannose; Lane 7, maltose; Lane 8, fucose; Lane 9, NANA.
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assay. Figure 3.12 shows that both activated (Lanes 6 and 8) and non-activated 
forms (Lanes 7 and 9) of CyaA bound to sheep erythrocytes. However, visual 
analysis of the intensity of the 200 kDa toxin bands present indicated that slightly more 
activated CyaA (Lanes 6 and 8) had become bound to the erythrocytes in comparison 
to the non-activated extracts (Lanes 7 and 9) tested. This suggested that either more 
activated CyaA was bound, or that bound activated CyaA was bound more stongly, in 
comparison to the non-activated form. There was also some degradation of the CyaA 
protein demonstrated by the laddering pattern of the 200 kDa protein, particularly in 
Lanes 1, 2, 6 and 7 of Figure 3,12.
The role of activation on binding specificity was further investigated by 
determining the binding of CyaA to various cell lines, namely Baby Hamster Kidney 
(BHK) cells , a murine macrophage cell line (J774.2) and a bovine lymphoma cell line 
(BL3). These cell lines were routinely cultivated in our department, and had been used 
by other groups investigating the toxicity of CyaA so were both convenient and of 
interest. The activated and non-activated forms of CyaA were also incubated with sheep 
erythrocytes as a control.
Figure 3.13 shows that activated CyaA purified from BP348 (pRMBl) (Lane 
1) and E.coli DH5aF'IQ (pCACT-3) (Lane 3) bound to J774.2 cells. Non-activated 
CyaA, (supplied by Dr Gareth Westrop, Division of Infection and Immunity, 
University of Glasgow) did not bind to this cell type (Lane 2, Figure 3.13). Only a 
small amount of non-activated CyaA purified from Exoli DH5aF'IQ (pDLACT-1) 
bound to these cells (Lane 4, Figure 3.13). These results suggest that activation of 
CyaA is important in potentiating binding of the toxin to certain cell types. However, 
we did not detect binding of activated or non-activated foiins of CyaA to either BHK or 
BL3 cells in this assay (Figure 3.13). The assay was repeated three times with BHK 
and BL3 cells, but no binding could be detected. BHK cells have been used routinely in 
adenylate cyclase toxicity assays by other investigators (Westrop et at ,1994; Westrop 
et al , 1996), strongly suggesting that the toxin does indeed bind to them. The
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F ig u re  3 .12  Role o f activation in binding o f CyaA to sheep erythrocytes.
Sheep RBCs (2 xlO^ cells/assay) were incubated with 100 pg/ml of dialysed extracts 
of CyaA purified from B.pertussis 348 (pRMBl) and recombinant strains of E.coli 
for 60 min at 37oC. Bound toxin was detected by as described in section 2.10. In
Lanes 1-4, 5 pg of toxin extracts were run as controls and in Lanes 5-9, 50pl samples 
were run. Lane 1, CyaA from BP348 (pRMBl); Lane 2, non-activated recombinant 
CyaA (pGW22)a; Lane 3, activated recombinant CyaAh; Lane 4, non-activated
recombinant CyaAc; Lane 5, 10 pg of untreated RBCs; Lane 6-9 , RBCs exposed to: 
Lane 6, CyaA from BP348 (pRMBl); Lane 7, non-activated recombinant CyaA 
(pGW22); Lane 8, activated recombinant CyaA; Lane 9, non-activated recombinant 
CyaA.
a gift from Dr Gareth Westrop, University of Glasgow 
h urea extract from E.coli DH5a FTQ (pCACT-3) 
c urea extract from E.coli DH5a FTQ (pDLACT-1 )
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Figure 3.13 Role o f  activation in binding o f  CyaA to different cell types
Cells assayed were sheep erythrocytes (2 x 10^/assay), and the J774.2, BHK and BL3
cell lines (5 x 10  ^cells/assay). Cells were incubated with 100 pg/ml of dialysed CyaA 
extracts for 60 min at 37°C. Bound toxin was detected as described earlier. Cells were 
incubated with: Lane 1, CyaA from BP348 (pRMBl); Lane 2, inactive recombinant 
CyaA (pGW22)^; Lane 3, active recombinant CyaAb; Lane 4, inactive recombinant 
CyaA^; Lane 5, lOpg of untreated cells.
 ^gift from Dr Gareth Westrop (University of Glasgow) 
b urea extract from E.coli DH5aFTQ (pCACT-3) 
c urea extract from E.coli DHSaF'IQ (pDLACT-1)
Sheep  R B C
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negative binding results obtained for this cell type may be due to an inherent 
insensitivity of the binding assay, resulting from the low number of BHK cells (5x10^) 
used in the assay in comparison to erythrocytes (2x10®). This may also explain the 
result obtained with the BL3 cell line. However,we also used relatively few (5x105) 
J774.2 cells in this assay, and detected binding of the activated form of CyaA. 
Therefore, it is possible that CyaA may have bound to BHK and BL3 cells in a manner 
which could not be detected by this assay system. Nevertheless, the results obtained 
with the sheep erythrocytes and J774.2 cells do suggest that activation may play a role 
in facilitating cell binding and / or determining cell specificity.
3.3 ANALYSIS OF RECEPTORS FOR ADENYLATE CYCLASE TOXIN
3.3.1 Investigation of protein receptors for adenylate cyclase toxin
A number of protein and in particular glycoprotein receptors for bacterial toxins, 
including those for diphtheria toxin (Makeda et a l , 1991) and the 5-endotoxin of 
Bacillus thuringiensis (Knowles and Ellar, 1986), have been described. With this in 
mind, analyses were carried out to determine if the receptor for CyaA on sheep 
eiythrocytes was proteinaceous in nature. Silver staining of an SDS-PAGE gel of sheep 
RBC membrane proteins revealed a variety of different molecular weight proteins 
(Lanes 1 and 2, Figure 3.14). These proteins were potential receptors for CyaA. 
The binding of CyaA to these membrane proteins, was analysed by a nitrocellulose 
overlay assay as described in Materials and Methods. In this assay membrane proteins 
were separated by SDS-PAGE, blotted onto nitrocellulose and overlaid with adenylate 
cyclase. To detect binding of CyaA to these proteins a system of immunodetection was 
initially used (Figure 2.2) involving sequential overlays of antibodies culminating in a 
colourometric reaction.
When these sheep RBC membrane proteins were blotted and probed with CyaA 
at 37.5 flg/ml (Blot A) and 75 pg/ml (Blot B), no binding was detected at either
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F ig u r e  3 .14  Silver stain o f membrane proteins isolated fron sheep erythrocytes
Membrane proteins were isolated from sheep erythrocytes (sRBCs), were separated 
by SDS-PAGE and visualised by silver staining as described in Materials and 
Methods. Lane 1, sRBC membrane proteins (5|Lig); Lane 2, sRBC membrane proteins
( 1 0 |ig).
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concentration to any of them (Figure 3.15). A control blot (Blot C) was also 
performed, in which CyaA was run on the SDS-PAGE gel adjacent to the membrane 
proteins and blotted. This blot was overlaid with buffer as a control, instead of CyaA 
and then processed in the same manner as before. On this blot the 200 kDa CyaA 
protein was detected (Lane 3, Blot C, Figure 3.15) This demonstrated that the 
assay system could detect CyaA, which had initially been run on a gel and blotted. 
However, the assay may not have been sensitive enough to detect small amounts of 
CyaA bound to the membrane proteins on the overlay blots.
In an attempt to amplify any binding by CyaA to the blotted proteins a system 
of radioisotope detection was employed (Figure 2.2). When CyaA was incubated for 
2 hours with blots of sRBC membrane proteins no binding was detected to any of the 
proteins using this system (Lanes 1 and 2, Blot A, Figure 3.16a). A similar 
result was obtained when CyaA was incubated overnight with an identical blot (Lanes 
1 and 2, Blot A, Figure 3.16b). Lane 3 of the control blot (B) in Figure 16a 
identified the 200 kDa CyaA toxin band which had been run on a gel adjacent to the 
membrane pro teins. The control blot (B) in Figure 3.16b also showed the presence of 
200 kDa CyaA in Lane 3, but there are also a number of protein bands showing up, 
and were probably degradation products of CyaA, or have resulted from over-exposue 
of the autoradiograph. Nevertheless, these results that CyaA run on a gel could be 
detected by this system and that the assay was working.
These results with the nitrocellulose overlay systems indicated that B. pertussis 
CyaA did not bind to proteins isolated from sheep erythrocytes membranes and 
suggested that such proteins would not act as receptors.
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F ig u r e  3 .15  Binding o f CyaA to membrane proteins separated by SDS-PAGE.
Membrane proteins, isolated from sheep erythrocytes (sRBC's), were separated by 
SDS-PAGE and transferred to nitrocellulose membranes by Western blotting. The 
blots were overlaid overnight with dialysed CyaA from BP348 (pRMBl) at 37.5 (A) 
or 75 |ig/ml (B) or with buffer (C) as a control.The overlaid blots were incubated 
with monospecific anti-CyaA serum prepared in rabbits. Binding was detected by 
means of peroxidase-labelled donkey, anti-rabbit antibodies as described in Materials 
and Methods. Lane 1, sRBC membrane proteins (5|ig); Lane 2, sRBC membrane 
proteins (10|Xg); Lane 3, CyaA control (lOjig).
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Figure 3.16a Binding o f  CyaA to membrane proteins separated by SDS- 
PAGE after a 2 hour incubation* Sheep RBC membrane proteins were separated 
by SDS-PAGE and transferred to nitrocellulose by western blotting. The blots were 
overlaid with either 75 pg/ml dialysed CyaA, purified from BP348 (pRMBl) (A) or 
buffer (B) as a control for 2h. The overlaid blots were then incubated with 
monospecific anti-CyaA prepared in rabbits. Binding was detected by subsequent 
overlays of biotinylated anti-rabbit antibodies and ^^Si.g^i-eptavidin followed by 
autoradiography as described in Materials and Methods. Lane 1, sRBC (5 pg); Lane 2, 
sRBC (10 |0 ,g); Lane 3, CyaA (10 fxg).
Figure 3.16b Binding o f  CyaA to membrane proteins separated by SDS- 
PAGE after an overnight incubation. Sheep RBC membrane proteins were 
separated by SDS-PAGE and transferred to nitrocellulose by western blotting. The 
blots were overlaid overnight with either 75 |Lig/ml of dialysed CyaA, purified from 
BP348 (pRMBl) (A) or buffer (B) as a control. The overlaid blots were then incubated 
with monospecific anti-CyaA prepared in rabbits. Binding was detected by subsequent 
overlays of biotinylated anti-rabbit antibodies and ^^^i.s^j-eptavidin followed by 
autoradiography as described in Materials and Methods. Lane 1, sRBC (5 |i,g); Lane 2, 
sRBC (10 fig); Lane 3, CyaA (10 jXg).
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3.3.2 Investigation of glycolipid receptors for adenylate cyclase toxin
To investigate glycolipid receptors for adenylate cyclase toxin the glycolipid 
fraction was obtained from sheep erythrocytes by extraction with chloroform : methanol 
as described in Materials and Methods (section 2.12.1). A chromatogram overlay 
procedure was employed to investigate the possible glycolipid receptors.
Before overlay analysis could be carried out, it was necessary to find a suitable 
solvent to separate and resolve the extracted lipids. Comparison of a range of solvents 
demonstrated that a solvent system of chloroform : methanol : KCl (0.1%) [ 5: 4: 1, by 
vol] resulted in the best separation of a control mixture of gangliosides and the sheep 
erythrocyte lipid extract (Lanes 1 and 2, chromatogram A, Figure 3.17). The 
TLC profile of the erythrocyte extract identified a number of components which were 
possible receptors for CyaA (Lane 2, chromatogram A, Figure 3.17). The other 
solvents systems tested, chloroform : methanol : water (65 : 25: 4, by vol) and 
chlorofrom : methanol : NH3  (2.5M) (60 : 40 : 9, by vol) gave much poorer separation 
of the lipid components (chromatograms B and C, Figure 3.17). Therefore, the 
chloroform : methanol : KCl solvent system was subsequently used to separate lipid 
components before overlays were carried out.
Binding of CyaA to lipids separated by TLC was initially tested by an overlay 
immunodetection-system similar to that developed to investigate protein receptors (see 
Figure 2.3, Materials and Methods section). When separated lipids were overlaid 
with CyaA for 2h, the toxin appeared to bind to a number of gangliosides (Lane 1, 
chromatogram B, Figure 3.18). However, some gangliosides components 
showed up positive in the control overlay, in which CyaA had been replaced with 
buffer in the overlay sequence (chromatogram C, Figure 3.18). CyaA bound to 
the ganglioside, GDib (Lane 1, chromatogram B, Figure 3.18), which showed 
up much less strongly in the control blot (Lane 1, chromatogram C, Figure
3.18).
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F ig u re  3 .17  Comparison o f solvents for lipid separation
Sheep RBC lipids and gangliosides mixture (see text) were separated by TLC 
using three solvent systems: A, chloroform : methanol : KCl (0.1%) [5: 4: 1, by 
vol]; B, chloroform : methanol : water [65 : 25: 4, by vol] or C, chloroform : 
methanol : NH3  (2.5M) [60 : 40 : 9 , by vol]. The TLC's were air dried and 
stained with resorcinol. Lane 1, Ganglioside mixture (150 |Xg); Lane 2 , sRBC 
total lipid (500 pg).
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F ig u r e  3 .18  Binding o f CyaA to lipids separated on thin-layer chromatograms - 
Immunodetection Run I. TLC plates were prepared and run as described in 
Materials and Methods and either stained with resorcinol (A) or overlaid for 2h 
with 50 pg/ml of dialysed CyaA (B) or buffer (C) as a control. The overlaid TLC's 
were incubated with monospecific anti-AC prepared in rabbits. Binding was 
detected by means of peroxidase-labelled donkey anti-rabbit antibodies. Lane 1, 
Ganglioside mixture (150pg); Lane 2, sRBC total lipid (500pg). Arrow shows 
possible binding of CyaA to GDjb (see text)
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When CyaA was incubated with TLC plates overnight the control overlay 
showed a similar pattern to the CyaA overlay (chromatograms C and B, Figure
3.19). It was not possible to detect if CyaA bound strongly to the Goib as described 
above because, the background staining of the overlaid chromatograms was so dark 
that it was not possible to determine differences between the control overlay 
(chromatogram C, Figure 3.19) and the overlays with CyaA (chromatogram  
B, Figure 3.19) itself. It was possible that the DAB developer, used to visualise 
binding may have non-specifically stained the chromatograms. Therefore the overlay 
procedure was adapted with the purpose of eliminating this background staining of the 
TLC plates. In the new system overlay with CyaA was followed by sequential overlays 
of rabbit anti-CyaA serum, biotinylated anti-rabbit semm, and finally 125i_stj;eptavidin. 
Autoradiography was used to visualise the binding of CyaA to lipids run on 
chromatograms (Materials and Methods, section 2.12.2). When TLC plates were run 
and incubated with CyaA or buffer (control) for 2 hours, a number of glycolipids 
showed up positive in the assay on both the CyaA overlay plate and control plate 
(autorad's B and C, Figure 3.20). It was possible that there were components in 
the anti-CyaA serum which were reacting with the chromatographed lipids and giving 
false positives in the controls. With the aim of reducing this, the incubation of CyaA 
with the TLC plate was increased from 2 hours to overnight and the subsequent 
incubation of anti-CyaA serum with the TLC plate was reduced from Ih to 30 min 
(Figure 3.21). However, when these changes were made lipids still showed up on 
the background (control) plate in which CyaA had been omitted (autorad C, Figure 
3.21).
Anti-CyaA serum [1/1000 dilution in blocking buffer (see Materials and 
Methods) was incubated overnight with a TLC plate which had been run as above to 
absorb out any components of the serum which were reacting with the lipids. The 
overlay was repeated with preadsorbed anti-CyaA serum replacing normal anti-CyaA 
serum. CyaA bound to components in the sRBC lipid extract and gangliosides mixture
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F ig u r e  3 .19  Binding o f CyaA to lipids separated on thin-layer chromatograms - 
Immunodetection Run 2. TLC plates were prepared as described in Materials and 
Methods, and either stained with resorcinol (A) or overlaid overnight with 50 pg/ml 
of dialysed CyaA (B) or buffer (C) as a control. The overlaid TLC's were incubated 
with monospecific anti-CyaA prepared in rabbits. Binding was detected by means of 
peroxidase-labelled donkey anti-rabbit antibodies. Lane 1, Ganglioside mixture (150 
|ig); Lane 2, sRBC total lipid (500 pg)..
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F ig u r e  3 .2 0  Binding o f CyaA to lipids separated on thin-layer chromatograms - 
Radio-isotope detection Run 1. TLC plates were prepared and run as described in 
Materials and Methods, and either stained with resorcinol (A) or overlaid for 2h with 
50 pg/ml of dialysed CyaA purified from BP348 (pRMBl) (B) or buffer (C) as a 
control. The overlaid TLC's were then incubated with monospecific anti-CyaA 
prepared in rabbits. Binding was detected by subsequent overlays of biotinylated anti­
rabbit antibodies and 125i-Streptavidin followed by autoradiography as described in
Materials and Methods. Lane 1, Ganglioside mixture (150 pg); Lane 2, sRBC total 
lipid (500 pg).
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F ig u r e  3.21 Binding o f CyaA to lipids separated on thin-layer chromatograms - 
Radio-isotope detection Run 2. TLC plates were prepared and run as described in 
Materials and Methods, and either stained with resorcinol (A) or overlaid overnight 
with 50 pg/ml of dialysed CyaA (B) purified from BP348 (pRMBl) or buffer (C) as 
a control. The overlaid TLC's were then incubated with monospecific anti-CyaA 
prepared in rabbits. Binding was detected by subsequent overlays of, biotinylated
anti-rabbit antibodies and •25i_streptavidin followed by autoradiography as
described in Materials and Methods. Lane 1, Ganglioside mixture (150pg); Lane 2 , 
sRBC total lipid (500pg).
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(Lanes 1 and 2, respectively, autorad B, Figure 3,22). Comparing the 
autoradiograph (B) with the stained plate (A) showed that CyaA bound to all the 
gangliosides in the mixture, namely GMi, GDia, GDib, and GTib with similar 
intensity observed for each ganglioside (Lane 1, autorad B, Figure 3,22). There 
was also strong binding observed between CyaA and some of the components of the 
sRBC lipid extract, although binding was not detected to all these components (Lane 
2, autorad B, Figure 3,22). Preadsorbing the anti-CyaA serum removed all the 
non-specific reactions with the gangliosides and most of the reaction with sRBC lipid 
components on the control plate (autoradiograph C, Figure 3.22). These results 
indicate that CyaA is able to bind to purified gangliosides and membrane glycolipids 
from sheep erythrocytes. However the observation that binding of CyaA was not 
detected to all the components of the sheep erythrocyte membrane extract suggests that 
there is a degree of specificity in the binding of CyaA
3.4 ANALYSIS OF PORE FORMATION BY ADENYLATE CYCLASE 
TOXIN
3.4.1 Pore formation by adenylate cyclase toxin in erythrocytes 
membranes
One of the sequela of the interaction of adenylate cyclase toxin with eukaryotic 
target cells is colloid osmotic lysis, due to pore formation. To study pore formation by 
CyaA in sheep erythrocyte membranes, haemolysis assays were carried out. Adenylate 
cyclase toxin purified from B.pertussis 348 (pRMBl) was haemolytic to sheep 
erythrocytes (Figure 3.23a and b). When CyaA was incubated with the erythrocytes 
there was an initial lag phase of approximately 60 min before haemolysis became 
evident. This was followed by a linear phase in which haemolysis increased with time 
and reached a maximum after 300 min (Figure 3.23a). CyaA also exhibited a linear
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F ig u r e  3 .2 2  Binding o f CyaA to lipids separated on thin-layer chromatograms - 
Radio-isotope detection Run 3 . TLC plates were prepared as described in Materials 
and Methods, and either stained with resorcinol (A) or overlaid for overnight with 50 
pg/ml of dialysed CyaA purified from BP348 (pRMBl) (B) or buffer as a control 
(C). The overlaid TLC's (B and C) were then incubated with anti-CyaA serum 
prepared in rabbits which had been preadsorbed to a TLC plate run as above. Binding 
of CyaA was detected by subsequent overlays of biotinylated anti-rabbit antibodies 
and I25i_streptavidin followed by autoradiography as described in Materials and
Methods. Lane 1, Ganglioside mixture (150pg); Lane 2, sRBC total lipid (500pg). 
Arrows shows components in ganglioside mixture and RBC lipid extract which 
CyaA bound to.
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Figure 3.23a Haemolysis o f  sheep erythrocytes by CyaA - Time course.
Sheep RBCs were incubated with 100 |ilg/ml of dialysed CyaA purified from BP348 
(pRMBl) and haemolysis measured at ODg^onm- Percentage haemolysis was calculated 
as described in Materials and methods. Bars represemt the mean ± SEM from 3 
determinations. Haemolysis by dialysed toxin buffer was <1%.
F igure  3.23b H aem olysis o f  sheep erythrocytes by CyaA- D ose  
response. Sheep RBCs were incubated with dialysed CyaA purified from BP348 
(pRMBl) for 300 min and haemolysis measured at OD540nm- Percentage haemolysis 
was calculated as described in Materials and Methods. Bars represent the mean ± SEM 
from 3 determinations. Haemolysis by dialysed toxin buffer was <1%.
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relationship between protein concentration and haemolysis. (Figure 3.23b). 
Therefore, haemolysis by CyaA was both time and dose-dependent.
The haemolytic activities of the recombinant and native forms of CyaA were 
compared (Figure 3.24). The recombinant form of CyaA exhibited similar kinetics of 
haemolysis to the native form, consisting of a lag phase followed by linear phase 
reaching a maximum after 300 min. Since the recombinant form of CyaA exhibited 
similar properties to the native form, and was therefore comparable, recombinant forms 
of activated and non-activated CyaA were subsequently used to examine the role 
activation played in pore formation. Non-activated CyaA did not exhibit haemolytic 
activity towards sheep erythrocytes after incubation for 300 min (Figure 3.25). 
Activation was therefore important in potentiating the haemolytic activity of CyaA.
3.4.2 Pore formation by adenylate cyclase toxin in liposomes
3.4.2.1 Preparation of liposomes
Liposomes were used as a model system to examine the specificity of the 
interaction of CyaA with membranes which leads to pore formation. Two methods of 
liposome preparation were tested. Aiming for reproduciblity and consistency of size, 
liposomes were initially prepared using a Liposomat (liposome maker). Liposomes 
were formed from mixed lipid:detergent micelles prepared in a buffer containing a 
fluorescent marker (calcein) by removal of the detergent by cross-flow dialysis (Section 
2.14.1). The second method used freezing and thawing of lipid mixtures in the 
presence of calcein to fuse small liposomes into larger ones. The excess calcein was 
removed by column chromatography (Section 2.14.2).
The amount of calcein which had been trapped inside the liposomes prepared 
by the two methods was compared. It was evident that there was considerably more 
marker trapped by the freeze-thawing method than by cross-flow dialysis (Figure 
3.26). Indeed cross-flow dialysis resulted in little marker being trapped. Pore
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F igure 3.24 E ffe c t o f  native and recom binant CyaA on sheep  
erythrocytes . Recombinant CyaA^ and native CyaA^ (100 |ig/ml) were dialysed and 
incubated with sheep erythrocytes and haemolysis measured at OD540nm- Percentage 
haemolysis was calculated as described earlier. Haemolyis by dialysed toxin buffers 
and by dialysed urea extract from E.coli DH5'a (pICNOH) was <1%.
IfJrea extract from E.coli DH5'a (pCACT-3).
^Extract from B.pertussis 348 (pRMB 1) purified by calmodulin agarose 
chromatography.
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Figure 3.25 Effect o f activation on haemolytic activity o f  CyaA 
Activated and non-activated CyaA were prepared as dialysed urea-extracts from E.coli 
D H 5'a (pCACT-3) and E.coli DH5'a (pDLACT-1) respectively, as described in 
Materials and Methods. Sheep RBCs were incubated with 100 |U,g/ml of the extracts 
and haemolysis was measured at ODg^onm described earlier. Haemolysis by 
dialysed toxin buffer and urea extract from E.coli DH5'a (pICNOH)was <1%.
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Figure 3.26 Trapping o f fluorescent marker by two methods o f  liposome 
production . Liposomes were prepared by freezing and thawing followed by 
chromatography (1) or cross flow dialysis (2) as described in sections 2.14.1 and 
2.14.2. After preparation liposomes were diluted in liposomes assay buffer (serial one 
in foue dilutions). The trapped fluorescent marker (calcein) was released by treating the 
liposomes with Triton X-100, and fluorescence (arbitrary units) measured after 30 min 
in a fluorescence spectrophotometer (Cytofluor 2300)
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formation studies required liposomes which had a relatively large amount of fluorescent 
marker trapped inside in order to assay the release of this marker by lytic agents. 
Therefore, the freeze-thawing method of liposome production was employed in future 
studies.
3.4.2.2 Pore formation in liposomes
Native CyaA elicited marker release from liposomes (Figure 3.27). When the 
liposomes were treated with 75 jig/ml of CyaA there was no detectable lag period in the 
release of the marker. Marker release increased with time and reached a maximum of 
40% after 300 min.The other concentrations of CyaA tested had similar effects on the 
liposomes but the rate of marker release was lower. These studies demonstrated that 
liposomolysis (lysis of liposomes) by native CyaA was both time- and dose- 
dependent.
The recombinant form of CyaA showed a similar pattern of marker release 
from liposomes when compared to the native form of CyaA (Figure 3.28) However, 
when the same concentration of native and recombinant CyaA were tested the native 
form showed slightly more marker release after 300 min than the recombinant form. 
We had a higher yield of the recombinant form and so used this in subsequent studies. 
The activated and non-activated forms of recombinant CyaA were examined to 
determine the role activation played in pore formation in liposomes (Figure 3.29). 
Non-activated CyaA did not elicit marker release from liposomes. This observation 
indicated that activation was important in potentiating pore formation by CyaA in 
liposomes.
The role of calcium, in the lysis of liposomes by activated CyaA, was 
investigated (Figure 3.30). Lysis of the liposomes by CyaA was absolutely 
dependent on the presence of calcium. The threshold level of calcium required for lysis
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Figure 3.27 Pore form ation by CyaA in liposomes
Liposomes composed of DMPC : C : DCP (see section 2.14.2) were treated with 
various concentrations of dialysed CyaA purified from BP348 (pRMBl). Percentage 
marker release was calculated by comparison with release elicited by Triton-X 100. 
Marker release by dialysed toxin buffer was <1%.
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Figure 3.28 Effect o f  native and recombinant CyaA on liposomes 
Native and recombinant CyaA were prepared from BP348 (pRMBl) and E. colt 
DH5'a (pCACT-3), respectively (see Materials and Methods) and dialysed. Liposomes 
composed of DMPC : C :DCP (see section 2.14.2) were treated with the extracts (100 
|ig/ml). Percentage of marker release was calculated by comparison with release elicited 
by Triton-X 100. Marker release by dialysed toxin buffer and urea extract from E.coli 
DH5'a (pICNOH) was < 1%.
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F igure  3.29 E ffec t o f  activation o f  CyaA on pore form ation  in 
liposomes. Activated and non-activated CyaA were prepared as dialysed urea-extracts 
from E.coli DH5'a (pCACT-3) and E.coli DH5'a (pDLACT-1) respectively, as 
described in Materials and Methods. Liposomes composed of DMPC : C :DCP (see 
section 2.14.2) were treated with the extracts (100 p,g/ml). Percentage of marker release 
was calculated by comparison with release elicited by Triton-X 100. Marker release by 
dialysed toxin buffer and urea extract from E.coli DH5'a (pICNOH)was <1%.
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Figure 3,30 Effect o f  calcium on pore formation by CyaA in liposomes.
Recombinant CyaA was dialysed against liposome assay buffer without calcium. 
Liposomes composed of DMPC :C:DCP were prepared as described in Materials and 
Methods in the absence of calcium. Liposomes were treated with the CyaA extract (100 
jig/ml) in the presence of 0-50mM calcium. Percentage of marker release was calculated 
by comparison with release elicited by Triton-X 100. Marker release by dialysed toxin 
buffer and urea extract fvovoE.coli DH5'a (pICNOH)was <1%.
< 1%.
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was between 0 and 2mM calcium. When the calcium concentration was increased above 
2mM there was no significant increase in lysis mediated by CyaA.
3.4.2.3 Specificity of interaction of adenylate cyclase toxin with 
liposomes of different composition
With the aim of looking at the specificity of the interaction of CyaA, liposomes 
were prepared from different lipid mixtures. Varying the lipids used to prepare the 
liposomes altered the composition of the lipid membrane bilayer upon which the toxin 
acted. The importance of surface charge of target liposomes was examined (Figure 
3.31). Adenylate cyclase mediated marker release without a lag period from liposomes 
with a negative surface charge. There was a lag period of 100-150min in marker release 
from liposomes with a positive or no net surface charge. Release from positive or 
uncharged liposomes reached much lower levels (5%), compared to negatively charge 
liposomes (25%), after 300min. Therefore the surface charge of liposomes had a 
considerable affect on subsequent lysis by adenylate cyclase toxin.
Liposomes were synthesized with a ganglioside [Trisialoganglioside (GTlb)] 
incorporated into their membranes with an equivalent surface charge density to the 
negatively charged liposomes prepared normally. Incorporation of the ganglioside had 
no effect on lysis of liposomes by CyaA when compared to negatively charged 
liposomes prepared normally (Figure 3.32). Lysis of liposomes with or without the 
ganglioside incorporated reached 25% after 300 min. These results suggested that 
membrane gangliosides, or GTib in particular, were not essential for initiation of pore 
formation by CyaA in liposmes. It is possible that a negative charge alone may be 
required for the successful interaction between CyaA and the liposomes.
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Figure 3.31 Effect o f  surface charge o f  liposomes on pore form ation by 
CyaA. Liposomes were prepared with different surface charges by altering their 
composition as described in Materials and Methods. Negative, positive or liposomes 
with no net charge were prepared from lipid mixtures consisting of DMPC : C: DCP, 
DMPC: C: SA or DMPC : C, respectively. Liposomes were treated with dialysed 
recombinant CyaA (100 |ig/ml). Percentage of marker release was calculated by 
comparison with release elicited by Triton-X 100. Marker release by dialysed toxin 
buffer and urea extract fmmE.coli DH5'a (pICNOH) was <1%.
Section 3 108 Results
a>I I
30 1
25 -
20 “
15 -
10 -
“■ Ganglioside 
■" no ganglioside
60 120 1800 240 300
Time (min)
Figure 3.32 Raie o f  gangliosides in pore form ation  by CyaA in 
liposomes. Liposomes were composed of DMPC : C Gxib (ganglioside) or 
DMPC : C : DCP (no ganglioside) Liposomes were treated with dialysed 
recombinant CyaA (100 p,g/ml). Percentage of marker release was calculated by 
comparison with release elicited by Triton-X 100. Marker release by dialysed toxin 
buffer and urea extract from E.coli DH5'a (pICNOH)was <1%.
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3 .4 .3  Pore formation by adenylate cyclase toxin in erythrocytes and 
liposom es
Liposomes were used as a model membrane system. In order to apply the 
results obtained above to eukaryotic cell membranes it was necessary to compare the 
lytic effects of CyaA on liposomes and erythrocytes (Figures 3.33a and b). Lysis of 
erythrocytes showed a lag period of approximately 60 min whereas lysis of liposomes 
occurred without a lag (Figure 33b). When the same amount of CyaA protein was 
applied to erythrocytes and liposomes, haemolysis reached completion ( 1 0 0 %) whereas 
lysis of liposomes only reached (40%), after 300 min. Therefore, the toxin was either 
only lysing 40% of the liposomes or causing 40% marker release from all of them or 
both. Increasing the concentration used to treat the liposomes increased lysis, but the 
amount of liposome lysis after 300 min was still considerably lower than haemolysis 
(Figure 3.33b). Therefore, the toxin was either only able to lyse some of the 
liposomes or cause some marker release from all of them or a combination of both. It 
was therefore necessary to be careful when making comparisons between the model 
membrane system and the eukaryotic cells themselves.
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3.33a Lytic effect o f CyaA on sheep erythrocytes and liposomes - Time 
course. Liposomes composed of DMPC : C : DCP and sheep erythrocytes were 
prepared as described in the Materials and Methods. The liposomes and erythrocytes 
were treated with dialysed recombinant CyaA (100 pg/ml) and lysis calculated as 
described earlier.
3.33b Lytic effect o f  CyaA on sheep erythrocytes and liposomes - Dose 
response. Liposomes composed of DMPC : C : DCP and sheep erythrocytes were 
prepared as described in the Materials and Methods. The liposomes and erythrocytes 
were treated with different amounts of dialysed recombinant CyaA for 300 min and 
lysis calculated as described earlier.
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4.1 PURIFICATION OF ADENYLATE CYCLASE TOXIN
In this study B.pertussis 348 containing the plasmid pRMB 1 was chosen for 
production of CyaA because this strain had been previously shown to produce CyaA 
with high enzymic and toxic (invasive adenylate cyclase) activities (Brownlie et al 
1988; Westrop et al, 1994). Indeed, with enzymic and toxic activities reported to be as 
much as 3-5 times higher than the wild type B.pertussis Tohama strain (Brownlie et al, 
1988), B.pertussis (pRMBl) was suitable for parts of this study which required high 
levels of CyaA. Since the discovery of CyaA (Fishel et al, 1970) a number of 
investigators have made attempts to purify and characterise it (see section 1.4.1,1). 
Complex methods for purification have been described (Hewlett et al, 1989; Gentile et 
al, 1989). These methods include hydrophobic interaction chromatography and sucrose 
gradient centrifugation as well as a calmodulin-affinity chromatography step.
. Urea extraction was the method chosen for the initial In this present study a 
two-step process was employed for purification of CyaA from B.pertussis 348 
(pRMBl) extraction of CyaA from whole cells and this was first described by Confer 
and Eaton (1982). Treatment of whole cells with urea yields high levels of CyaA and 
was of particular use here because CyaA could be maintained in a stable form in urea 
solutions for several months (Confer and Eaton, 1982; Pearson et al, 1987; Kazi,
1992). Calmodulin-agarose (CaM) affinity chromatography was the next stage used in 
the purification of CyaA. This method of purification has been adopted by other 
investigators (Bellalou et al, 1990; Kazi, 1992; Westrop et al, 1994) and constituted a 
relatively simple and rapid method for purifying CyaA from B.pertussis.
By the two-step purification process full length (200 kDa) CyaA, which reacted 
with monospecific anti-CyaA serum, was purified (Figures 3.1a and b). In the 
purification process a 50-60 kDa polypeptide was also found in the CaM-agarose 
purified samples of CyaA (Figure 3.1a), A number of other studies have also 
reported the co-purification of a low molecular weight polypeptide during the
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purification of CyaA (Hewlett and Wolff, 1976; Wolff et al, 1984; Shattuck et al, 1985; 
Kessin and Franke, 1986; Ladant et al, 1986; Friedman, 1987). This polypeptide is a 
degradation product corresponding to the N-terminal catalytic domain of CyaA (Rogel 
et al, 1988; Ladant et al, 1989; Bellalou et al, 1990). In the present study the N-terminal 
degradation product was probably co-purified with the holotoxin because, as has been 
reported previously, this fragment contains the CyaA calmodulin binding site (Glaser et 
al, 1988a; Ladant et al, 1989). Results obtained in the present study in subsequent 
toxicity and pore-formation assays were not attributed to this fragment because, as has 
been reported in other studies, it is non-toxic and non-lytic to target cells (Hewlett et al, 
1989; Rogel et al, 1989; Rogel et a l , 1991).
The functional significance of CyaA activation was studied by preparing 
activated and non-activated forms of CyaA from two recombinant E.coli strains which 
co-expressed cya A with cya C or expressedcya A alone in an expression system 
(Figure 2.1) described previously by Betsou et al (1993). Urea extraction from these 
recombinant strains yielded a 200kDa protein which was relatively free from 
contaminating host cell protein as determined by Coomassie blue staining of SDS- 
PAGE gels (Figure 3.4a). Any contribution of contaminating protein from the host 
strain {E.coli DH5aFIQ) was controlled for in assays by the incorporation of a control 
consisting of a urea extract from the host strain which had not been transformed with 
the recombinant plasmids harbouring the cya inserts.
4.2 CHARACTERISATION OF ADENYLATE CYCLASE TOXIN
CyaA is an invasive adenylate cyclase toxin (Hanski, 1989). The toxin is 
characterised by its ability to enter mammalian cells whereby it is activated by host cell 
calmodulin to convert ATP to cAMP leading to impairment of cell function (Confer et 
al, 1984).
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In the present study the extracts of CyaA were characterised for their enzymic 
activity and also their toxicity towards BHK cells. The B.pertussis and E.coli extracts 
of CyaA had relatively high enzymic activities of 26-42 jimol cAMP/min/mg protein. 
The specific enzymic activity of the calmodulin-agarose purified extract from 
B,pertussis 348 (pRMBl) was 20-fold higher than the levels reported for CyaA 
purified by a similar method from the same strain by Kazi (1992). Rogel et al (1989) 
also reported purification of CyaA with an enzymic activity of 387.5 fimol 
cAMP/min/mg protein from B.pertussis 348 (pRMBl). However, in the study by 
Rogel et al (1989) the urea extract from B.pertussis 348 (pRMBl) was concentrated by 
ultra-filtration and partially purified by gel-filtration prior to CaM-agarose 
chromatography purification of CyaA. The current study was not a study on methods 
of purification of CyaA rather it was a study on the mode of action. The extracts were 
relatively free from contaminating material as determined by Coomassie staining of 
SDS-PAGB gels and although the enzymic activity was lower than the activity 
described by Rogel et al (1989) further purification was not considered necessary for 
the puiposes of the study .
The extracts from B.pertussis and E.coli were assayed for their toxic activity by 
a novel toxicity assay which has been developed by Westrop et al (1994). Invasive 
adenylate cyclase activity (toxicity) of CyaA is usually determined by measurement of 
intracellular cAMP levels. The procedure is lengthy and time consuming and after 
incubation with CyaA, cells require further extraction with HCl or sodium acetate 
followed by a number of centrifugation steps (Hanski and Farfel, 1985; Hewlett et al, 
1989; Ladant et al, 1989; Leusch et al, 1990) with measurement by a radioimmuno 
protein-binding assay (Gillman, 1970). The shape change assay which was developed 
in this department was relatively quick, free of isotopes and required only 90 minutes 
of incubation between CyaA and BHK cells before cells were fixed, stained and 
toxicity measured by computer aided image-analysis. The assay has been previously 
shown to be >11-fold more sensitive than traditional methods of intracellular and cAMP
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measurement and > 150-fold more sensitive than haemolysis assays (Westrop et al, 
1994). This novel toxicity assay demonstrated that the activated forms of CyaA purified 
from B.pertussis and E.coli possessed toxic activity which was absent from the non­
activated form of CyaA, and was in agreement with results obtained using traditional 
toxicity assays (Barry ar rzZ, 1991; Betsou a/, 1993 Hewlett era/, 1993). Hewlett era/ 
(1993) found that the absence of toxic activity of non-activated CyaA could be 
alleviated by artificially injecting CyaA into Jurkat cells.
4.3 CELL-BINDING OF ADENYLATE CYCLASE TOXIN
The full sequence of events during the interaction of CyaA with target cells has 
not yet been fully elucidated. However, the first stage in the successful interaction of 
CyaA and the other RTX toxins with target cells is cell-binding or cell-association. To 
examine the binding of CyaA to cells a whole-cell binding assay was employed which 
utilised the fact that a mono-specific anti-CyaA antibody was available which could 
detect the presence of CyaA in immunoblots of toxin-treated membranes (see section 
2.10). The assay was relatively simple and gave some interesting qualitative data about 
the specificity of binding of CyaA to erythrocytes and nucleated cell types and the role 
that activation played in this association.
In this present study it was demonstrated that CyaA could bind to / associate 
with sheep erythrocytes in a time and dose-dependent manner (section 3.2.1). 
However, the majority of CyaA was bound within 30 minutes, and binding increased 
only slightly after 60 and 120 minutes, as detected by immimoblotting of toxin-treated 
membranes (Figure 3.6). In general, these results were in accordance with the 
findings of a study by Rogel et al (1991). In that study, which utilised a similar binding 
assay, binding of CyaA to sheep erythrocytes could be detected within 5 minutes. 
However, in contrast with the results presented here, Rogel et al detected a 
considerable increase in CyaA binding with time. These differences may be attributed to
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the fact that in this study sheep erythrocytes were incubated with a lOOjig dose of CyaA 
while Rogel et al used only 2.5jig. In the current study by using forty times more toxin 
than Rogel et a l , it is possible that the erythrocytes were swamped with such high 
levels of toxin that increases in binding with time could not be detected or that the 
excess of toxin caused cell lysis leading to loss of bound material. However, a related 
study on E.coli HlyA, another RTX toxin, also found that the majority (85-95%) of 
toxin became bound within 60 minutes (Eberspacher et al, 1988).
Whereas time-dependent binding of CyaA to erythrocytes was not observed 
with the time-scale used in the present study, for the reasons described above, it was 
found that as the concentration of CyaA was increased from 5-100 (ig/ml there was a 
visible and linear increase in cell-bound toxin and that there was no apparent end-point 
(plateau) of binding reached (Figure 3.7). This result concurs with an earlier study on 
E.coli HlyA which quantitatively demonstrated by ELISA that the amount of cell- 
bound HlyA increased as a linear function of the toxin dose applied such that HlyA did 
not display saturatability in its binding to erythrocytes (Eberspacher et al, 1988). The 
results presented here give further credence to the hypothesis that the binding of CyaA, 
and probably other RTX haemolysins is non-saturatable and therefore non-specific.
There has been limited research into the specificity of the initial interaction of 
CyaA with target cells. CyaA has broad range specificity so it unlikely to interact with a 
specific receptor and indeed may interact with molecules that are common to many if 
not all eukaryotic cell surfaces. A study by Gordon et al (1989) found that pre-treatment 
of CHO cells with trypsin (5-2000|ag/ml) for 30 minutes did not affect subsequent 
intoxication by CyaA, as measured by intracellular cyclic AMP levels. The present 
study has extended and corroborated these findings by demonstrating that pre- 
trypsinisation not only did not inhibit haemolysis of sheep erythrocytes by CyaA but 
actually increased the susceptibility of the cells to the toxin (Figure 3.9b). Indeed, the 
haemolytic activity of CyaA was directly dependent on the concentration of trypsin used 
to treat the erythrocytes. However, in contrast, the binding of CyaA to trypsinised
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cells, as detected by immunoblotting of toxin treated membranes, decreased 
considerably (Figure 3.9a). This was not due to degradation by residual trypsin or a 
cell surface protease (Figure 3.12). Trypsinisation of the erythrocytes may allow 
CyaA greater accessibility to the hydrophobic membrane and hence allow increased 
penetration by stripping-off hydrophilic cell surface structures such as 
glycoproteins.The increased lysis of the cells by the high levels of CyaA encounteriung 
the membranes may have resulted in release or solubilisation of cell-associated toxin 
such that it could not be detected by the binding assay.
The finding from this study that CyaA can productively associate with cells 
treated with high concentrations of trypsin and cause haemolysis along with the 
findings of Gordon et al (1989) are strong indications that CyaA does not interact with 
a protein receptor. Alternatively, CyaA may interact with a trypsin-resistant protein 
receptor. This is unlikely because it was also found that another protease (proteinase K) 
could also potentiate the haemolytic activity of CyaA (data not shown). These results 
were confirmed and extended by the overlay and liposomes assays (see sections 3.3 
and 3.4)
To determine if CyaA interacted with specific sugar molecules, which are 
present on eukaryotic cell-surfaces on either glycolipids or glycoproteins, the inhibitory 
effects of a variety of sugars on the binding of CyaA to sheep erythrocytes was 
investigated. In this study it was found that none of the sugars tested; D-galactose, D- 
glucose, D-mannose, D-maltose, D-fucose or N-acetyl neuraminic acid (NANA), 
inhibited the binding of CyaA to sheep erythrocytes. It has been reported that treatment 
of human phagocytes with neuraminidase inhibits the toxicity of CyaA and suggested 
that neuraminic acid moieties on gangliosides may be receptors for CyaA (Gable et al, 
1985). However in the present study NANA did not block binding of CyaA to 
erythrocytes. It is possible that the concentration of the sugars was too low to block 
binding of CyaA, but at a concentration of 50mM this is unlikely. A study by Escuyer 
and Collier (1991) into the receptor fovBacillus anthracis protective antigen (PA) used
Section 4 117 Discussion
13 monosaccharides, gangliosides and glycoproteins at the same concentration as in 
this study, to determine if they inhibited the interaction of PA with CHO cells, and 
binding-inhibition was detected.
It is probable that the initial interaction of CyaA with receptor-like molecules 
may be a weak non-specific one, facilitating penetration of the molecule into the 
membrane. Alternatively, in bulk solution the CyaA toxin molecule may be folded 
differently than when it is in association with cell membranes, possibly as a response to 
differing dielectric constant in the immediate vicinity of the membrane surface, and that 
an initial non-specific association of CyaA with the target cell membrane, may result in 
partial unfolding of the toxin molecule allowing it to anchor itself to the membrane (via 
negatively charged molecules such as gangliosides). This may be followed by pore 
fomiation and deliveiy of the catalytic unit to the cell interior.
4.4 ROLE OF ACTIVATION IN CELL-BINDING OF ADENYLATE 
CYCLASE TOXIN
CyaA is a member of the RTX toxins family and in common with the other 
RTX toxins it is now well established that it is activated by means of a C-gene-mediated 
modification (Barry et al, 1991; Coote, 1992). It has been suggested that activation of 
RTX toxins may be important in determining cell-specificity (Forestier and Welch, 
1990; Westrop et al, 1997). To study this, the binding of activated and non-activated 
CyaA to different cell types was investigated (section 3.2.4). In this study it was found 
that activated and non-activated derivative of CyaA could both bind to / associate with 
sheep erythrocytes, although on visual examination of Western Blots (Figure 3.12) 
of toxin-treated membranes, slightly more activated CyaA had become bound. Using 
Jurkat cells as a model for the interaction of CyaA with cells, Hewlett et al (1993) have 
also demonstrated that activation is not required for the initial interaction of CyaA with 
cells. However, in addition they demonstrated a quantifiable difference between the
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interaction of the different forms of CyaA with cells, in that 99% of the cell-associated 
non-activated toxin was sensitive to trypsinisation whereas 20% of cell-associated 
activated toxin was trypsin resistant. It can be concluded from their study that CyaA 
produced from cells lacking CyaC is defective in the insertion and delivery of the 
catalytic unit to cells, and therefore more sensitive to proteolysis.
Bauer and Welch (1996) have recently demonstrated that acylated and non- 
acylated HlyA bind equally well to sheep erythrocytes, and that acylated HlyA can 
displace unacylated HlyA from the cell surface. They suggested that activated HlyA has 
a slightly stronger affinity for the cells surface than the non-activated form which is in 
agreement with the results presented here for CyaA (Figure 3.12).
Whereas, there was only a minimal difference in the binding of the activated and 
non-activated forms of CyaA to sheep erythrocytes, this was not the case when the 
binding was examined using a murine macrophage cell line (J774.2). It was found that 
binding of non-activated CyaA was significantly lower and almost absent compared to 
the activated form (Figure 3.13). These results are the first evidence of differences in 
affinity between activated and non-activated CyaA. It is possible that the results with 
this cell line reflect the true significance of activation of CyaA, which may be to 
selectively target activated CyaA to cells of the immune system such as macrophage. 
The haemolytic activity of CyaA occurs after a 30-60 minute lag period and requires 
relatively high concentrations of toxin, whereas intoxication is without a discernable lag 
and occurs in the presence of relatively low concentrations of CyaA (Rogel et al, 1991). 
During the B.pertussis infection of the upper respiratory tract the organism and toxins 
liberated such as CyaA will rarely encounter erythrocytes unless there is damage to the 
respiratory epithelium. Therefore erythrocytes, although useful as models of pore- 
formation by CyaA, nucleated cell types may have more relevance to the in vivo 
situation which CyaA will encounter during pertussis.
Interestingly, no binding of activated or non-activated CyaA was detected with 
BHK or BL3 cells (Figure 3.13). This was particularly surprising since CyaA was
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shown to be toxic to BHK cells in the Shape-Change assay (Figure 3.5). It is 
possible that the solubilisation conditions of hypotonic lysis of these cell types may 
have resulted in the dissociation of bound toxin such that in the subsequent washing 
steps CyaA was not recoverable or that the assay was not sensitive enough to detect the 
small amount of cell-bound toxin.
Recently the mechanism of activation of CyaA has been investigated, and it has 
been found that activation occurs by a similar mechanism to that described for HlyA by 
acylation of the protoxin (Hackett et al, 1994; Heveker et al, 1994). Heveker et al 
demonstrated that random transfer of fatty-acyl groups to inactive CyaA conferred 
haemolytic and toxic activities to the molecule (Heveker et al, 1994). Recently it has 
been shown that wild-type activated CyaA is palmitoylated at lysine-983 whereas 
inactive CyaA is not (Hackett et al, 1994).
A very recent and extensive study on E.coli haemolysin has produced some 
interesting findings which confirm the results presented here concerning the role of 
activation with regard to target cell specificity (Pellet and Welch, 1996). In the study the 
cytotoxic phenotype of E.coli haemolysin mutants bearing substitutions in or around 
the known in-vitro activation sites of HlyA was tested for cytotoxicity towards three 
different cell types; sheep erythrocytes, BL-3 cell line and Raji cell line (human B-cell 
lymphoma). The study demonstrated that the lytic activity of HlyA towards sheep 
erythrocytes and Raji cells depended on the presence of two acylated lysines in the 
putative toxin-activation site, whereas the cytotoxic activity of HlyA towards BL-3 cells 
did not require this modification. The results presented here along with the results 
described by Pellet and Welch (1996) suggest that in vivo, activation of CyaA and 
HlyA may be required for targeting these toxins towards different cell-types.
A recent study by Iwaki et al (1996) examined the toxic activities of a set of 
deletion derivatives of CyaA and found that there was no dedicated cell-binding domain 
of CyaA, rather that structural integrity of CyaA and co-operation of all the domains of 
CyaA and fatty acylation was required for cell-association and subsequent toxicity. This
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is in contrast to other more specific toxins such as Pseudomonas exotoxin A which has 
a discrete cell-recognition domain essential for toxin-receptor interaction (Wick et al,
1990). Activation by acylation may be a means for directing and anchoring CyaA and 
other RTX toxins in target cell membranes. A recent study be Westrop et al (1997) has 
shown that a region spanning the proposed actylation site of the highly specific RTX 
leukotoxin LktA, produced by Pasturella haemolytica , and the adjacent glycine rich 
repeat region plays a major role in determining specificity.
It should noted that although traditionally B.pertussis has been considered an 
extra-cellular pathogen which multiplied on the surface of the respiratory epithelium 
without internal dissemination, it has also been found in alveolar macrophage early in 
infection (Gray and Cheers, 1967). In addition, in vitro can enter and survive 
intracellularly in various cell types, including macrophages, polymorphonuclear 
leukocytes, epithelial cells, Hela cells, HEp2 cells and CHO cells (Evanowich et al, 
1989; Lee et al, 1990; Mouallem, 1990; Saukkonen et al, 1991; Steed et al, 1991; 
Roberts et al, 1991; Friedman et al, 1992; Masure, 1992). Recently it has been 
demonstrated that CyaA itself can be delivered by entry of whole bacteria into target 
cells, and that indeed in these circumstances the toxic activity of CyaA actually 
contributes to the survival of B.pertussis inside cells (Mouallem et a l , 1990; Masure, 
1993). Moreover, using a macrophage cell line Khelef et al (1993), showed that 
B.pertussis promotes macrophage apoptosis (programmed cell-death) and that CyaA 
was essential in this process whereas pertussis toxin was not required. This mode of 
entry may have considerable significance to the pathology of whooping cough whereby 
it may be a means by which the organism establishes an intracellular reservoir from 
which it can infect neighbouring cells and tissue surfaces and also other susceptible 
individuals. Repression of virulence factors may be importance if as part of its life cycle 
B.pertussis survives in its host in a quiescent intracellular state
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4.5 CELLULAR RECEPTORS FOR ADENYLATE CYCLASE TOXIN
Glycoprotein receptors have been previously described for a number of bacterial 
protein toxins including Bacillus anthracis protective antigen (Escuyer and Collier,
1991), E.coli heat-stable^ toxin (Dreyfus and Robertson, 1984), diphtheria toxin 
(Mekada, 1991) 2ind Bacillus thuringiensis 9-endotoxin (Knowles and Ellar, 1984). A 
number of techniques have been applied to identify proteinaceous receptors. Loss of 
susceptibility to toxin after enzymic pre-treatment has been the first step in the 
identification of protein receptors for a number of bacterial toxins. Escuyer and Collier 
demonstrated that by pre-treating CHO cells with trypsin or pronase, the receptor for 
B.anthracis PA was proteinaceous in nature (Escuyer and Collier, 1991). Similar 
studies have been the starting point for identification of protein receptors for diphtheria 
toxin (Moehring and Crispell, 1974) and E.coli heat-stable anterotoxin (Frantz and 
Robertson, 1983). In this present study it was shown that pre-trypsinisation did not 
inhibit subsequent haemolysis of sheep erythrocytes by CyaA, rather it potentiated it 
(section 4.3). CyaA exhibits little or no specificity in its cellular attack and will lyse 
erythrocytes and is toxic to a wide range of nucleated cell types (see section 1.5). It is 
therefore unlikely that CyaA interacts with a specific receptor.
However, to investigate this further a nitro-cellulose overlay assay was 
developed. Nitro-cellulose overlay assays have been used previously by other 
investigators to isolate glycoproteins receptors for bacterial toxins such as
B. thuringiensis 9-endotoxin and Pseudomonas aeruginosa exotoxin A (Knowles and 
Ellar, 1986; Forristal et al, 1991; Thompson et al, 1991) and for other bacteria such as 
Mycoplasma pneumoniae and oral streptococci (Geary et al, 1990; Murray et al, 1992). 
The assay involved the transfer of sheep erythrocyte membrane proteins, previously 
separated by SDS-PAGE, to nitro-cellulose by Western blotting. The immobilised 
proteins were then probed with CyaA and binding analysed by means of antibodies. In
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the present study no binding of CyaA was detected to the membrane proteins isolated 
from sheep erythrocytes.
Gordon et al (1988) found that agents such as cytochalasin D, ammonium 
chloride and chloroquinoline, which interfere with receptor-mediated uptake 
mechanisms, had no effect on the uptake of CyaA, prepared as a urea extract from 
whole cells of B.pertussis strain 338, into CHO cells (Gordon et al, 1988). A related 
study, which measured the entry of CyaA, partially purified from the culture 
supernatant of B.pertussis (Tohama phase 1 strain) into a murine neuroblastoma cell 
line (NlE-115), confirmed these earlier findings (Donovan and Storm, 1991). In 
general bacterial toxins like diphtheria toxin and Pseudomonas aeruginosa exotoxin A 
that enter target-cells by receptor-mediated endocytosis interact with specific 
glycoproteins on cell surfaces (Morris, 1990; Mekada et al, 1991) whereas toxins such 
as cholera toxin and E.coli LT that penetrate cell membranes directly (Eidels et al, 
1983) interact with glycolipid-type receptors. The evidence presented here suggests, in 
common with other bacterial toxins which do not enter cells by receptor-mediated 
endocytosis, that CyaA does not interact with specific glycoproteins
To further investigate the hypothesis that CyaA may interact directly with 
glycolipid-type receptor(s) a thin-layer chromatogram overlay assay was developed. 
The thin-layer chromatography overlay assay was first described by Magnani et al 
(1981) for detection of cholera toxin binding to gangliosides. Since then the technique 
has been applied successfully to identify the glycolipid-type receptors for a number of 
bacterial toxins including pertussis toxin (Brennan et al, 1991; Hausmann and Burns,
1993) shiga-like toxin (Samuel et al, 1990) and microbial adhesins (Hansson et al, 
1985; Payne et al, 1993; Willemsen and Graaf, 1993; Cameron and Douglas, 1996). 
The technique uses the principal that lipids separated and immobilised by thin-layer 
chromatography can be overlaid with ligands such as bacterial toxins and adhesins and 
binding can be detected by enzyme- or isotope -labelled antibody systems.
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In the current study a number of technical difficulties were encountered in the 
development of the TLC overlay technique. Initially using an immuno-detection method 
(see Figure 2.3) there was background staining of the chromatograms such that it 
was difficult to differentiate between the background and specific binding of CyaA. The 
system used to detect the binding of CyaA, i.e. initial incubation with CyaA followed 
by sequential overlay of TLC's with antibodies prior to visualisation of binding by 
means of diaminobenzidine (DAB) developer, was adopted from Western Blotting and 
was found to be unsuitable for TLC. This was probably due to the fact that once the 
TLC's had been run they were coated with a solution of poly-isobutylmethacrylate to 
present and orientate the lipids prior to the overlay stages. It is possible that there was a 
reaction occurring between the developer mixture and the coated surface of the 
chromatograms.
Another problem encountered with this technique was cross-reactivity between 
the anti-CyaA serum with components of the sheep erythrocyte extract. The serum was 
mono-specific and was raised by Dr Yasmeen Kazi (University of Glasgow) in a rabbit 
against sonicated nitro-cellulose containing CyaA. It is possible that the rabbit used to 
prepare the serum had previously encountered ovine antigens and elicited an immune 
response. This may have yielded some ovine-cross reactivity in the anti-CyaA serum. 
However, it is of note that in the cell-binding assays and nitro-cellulose overlay assays 
no cross-reactivity was detected between anti-CyaA and the sheep erythrocyte 
membrane proteins. Therefore, it is possible that the binding of the anti-CyaA seram to 
the lipid components of the membrane extract and gangliosides was a non-specific 
adsorption. Nevertheless, the cross-reactivity with the components was successfully 
removed from the anti-CyaA serum by pre-adsorbing the serum to pre-run components 
on a TLC plate.
The TLC overlay assay demonstrated that CyaA could bind to a range of 
gangliosides and that the toxin did not display a specificity for any of those tested 
(GMj, GDia, GDib, and GTib). Binding of CyaA was detected to some but not all of
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the components of the sheep erythrocyte lipid extract. This is the first evidence that 
CyaA can bind directly to lipid components extracted from sheep erythrocyte 
membranes and also purified gangliosides. Along with the finding that CyaA does not 
bind to membrane proteins from sheep erythrocytes these results suggest that CyaA 
does not interact with a specific receptor but may interact with a range of components 
on the cell surface which may facilitate insertion into the cell membrane. It would be 
interesting to determine the degree of binding of non-activated CyaA to the same 
components, but unfortunately when these experiments were carried out an extract of 
non-activated CyaA was not available.
4.6 PORE-FORMATION BY ADENYLATE CYCLASE TOXIN
It had been shown previously that CyaA can lyse erythrocytes by colloid 
osmotic lysis by formation of pores with an approximate diameter of 0.6 nm (Ehrmann 
et al, 1991; Rogel et al, 1991). The haemolytic activity of CyaA is weak compared to its 
toxic (invasive adenylate cyclase) activity and haemolysis is reported to occur after a lag 
phase of 30-60 minutes (Ehrmann et al, 1991).
The results presented here demonstrate the haemolytic activity of CyaA purified 
from B.pertussis 348 (pRMBl) and from a recombinant E.coli strain towards sheep 
erythrocytes. The haemolytic activities and kinetics of haemolysis exhibited by the 
CyaA extracts purified from B.pertussis and E.coli were similar. A study by Sebo et al 
(1991) found recombinant CyaA expressed an E.coli strain to have lower haemolytic 
activity then CyaA purified from B.pertussis 18323. In that study cyaA and cyaC 
were expressed on separate plasmids in the same E.coli host. The results presented 
here demonstrate that when the cyaA and cyaC genes are expressed in the same high- 
copy number plasmid then there is little difference in the haemolytic activities compared 
to B.pertussis CyaA. These results are in agreement with a study by Betsou et al
(1993) which compared the haemolytic activities of CyaA produced by co-expression
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of cyaA and cyaC on the same plasmid with a two plasmid system and found that co­
expressing of the two genes to be more efficient for production of activated CyaA.
Haemolysis mediated by these extracts increased with the dose applied and the 
time of incubation. These results are in agreement with studies carried out by other 
investigators (Ehrmann aZ, 1991; Rogel e?aZ, 1991; Bellalou era/, 1993). There was 
a lag period of between 30-60 minutes before haemolysis became evident. Other studies 
have reported a lag-phase before haemolysis became apparent (Ehrmann et al, 1991; 
Rogel et al, 1991).The most recent studies into the nature of the pore formed by CyaA 
have indicated that the toxin forms small channels in membranes which are polarity and 
voltage dependent and suggest that the pore formed is an oligomer and produced by the 
interaction of at least three toxin monomers (Benz et al, 1994; Szabo et al, 1994; Otero 
et al, 1995).
Interestingly, considering that pertussis is a human disease, it has been reported 
that human erythrocytes are relatively resistant to haemolysis by CyaA but still sensitive 
to the toxicity of CyaA, albeit at lower levels compared to erythrocytes from other 
mammalian species (Rogel et al, 1991). This effect can abrogated by pre-treatment of 
cells with a protease inhibitor (N-ethyl malemide). It is likely that human erythrocytes, 
unlike erythrocytes from other species which will not have had the selective pressure 
since B.pertussis is a human pathogen, may have evolved to become resistant to 
haemolysis by CyaA.
In the study presented here liposomes were prepared to investigate the effect of 
membrane composition on the lytic activity of CyaA. These experiments demonstrated 
that CyaA could permeabilise liposomes in a time and dose-dependent manner, an 
observation which had been previously reported by Gordon et al (1989). Unlike 
haemolysis the lytic effect of CyaA on liposomes proceeded without a lag period. This 
is presumably because liposomes do not have the same constraints on membrane 
integrity that erythrocytes have and can leak contents without lysis. The lipsomes assay 
measured the release of a fluorescent marker calcein, whereas haemolytic assays
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measure that release of haemolglobin a cellular protein. Membrane disruption in 
erythrocytes requires osmotic swelling before release of haemoglobin. Erythrocyte 
membrane permeablisation will by definition be much greater than that associated with 
permeability changes involving release of a smaller chemical marker from liposomes: 
hence the lag period.
Despite the absence of a lag period the final marker release from liposomes was 
low (30-40%) compared to the haemoglobin release in haemolysis (100%) for the 
comparable time period. In a study by Gordon et al, (1989) the marker release by CyaA 
from liposomes also plateaued at a similar low level (approximately 40%). The 
liposome permeability assays were carried out at room temperature without temperature 
control because no thermostatic control was available on the microplate reader in which 
the experiment was carried out. The haemolysis assays were carried out at 37®C. This 
difference in marker release with time can probably be attributed to these temperature 
differences.
It has been previously reported that gangliosides may act as putative receptors 
for CyaA (Gable et al, 1985; Gordon et al, 1989). To investigate this a comparison was 
made of CyaA mediated marker release from liposomes with or without gangliosides 
incorporated. It was found that a negative charge on the liposomes was enough to make 
them susceptible to CyaA and that there was not an absolute requirement for the 
presence of gangliosides. Furthermore, assays in which the charge of the liposomes 
was altered showed that negatively charged liposomes were much more susceptible to 
CyaA than positively charged or neutral liposomes. These results are interesting in the 
light of a study performed by Rapitis et al (1989) who found that cations such as poly- 
L-lysine incubated with CHO cells could block the invasive activity of CyaA and 
concluded that the cations were blocking anionic sites on the membrane. In addition 
they found that treatment of CHO cells with neuraminidase would not block the CHO 
intoxication. The results presented here are further evidence to suggest that the 
interaction of CyaA with membranes may be at the level of a charge-charge interaction
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with negatively charged moeties on the membrane surface acting as the initial 
recognition sites. It is possible that these sights may non-specifically interact with the 
positively charged glycine-rich repeats on the toxin molecule
The results presented here for haemolysis and marker release for liposomes 
demonstrate that CyaA activation is an absolute requirement for its haemolytic activity. 
Recently, other investigators have described a similar phenomenon with haemolysis 
(Betsou et al, 1993; Hewlett, et al 1993). It is possible that the initial non-specific 
charge association between CyaA and the target cell membrane is followed by a 
stronger anchoring in the membrane allowing penetration and expression of toxicity and 
eventual development of haemolysis.
In conclusion the interaction of CyaA with target cells is complex but it is 
gradually becoming understood.This study has revealed further aspects of the non­
specific interaction of CyaA with cells and their lipid components. The importance of 
membrane surface charge has also been demonstrated. Further domain dissection 
studies will hopefully reveal more about the regions of the protein which interact with 
these negatively charged recognition sites. The role of activation of CyaA is still an area 
which requires intensive research but results from the present study indicate that 
activation may be a means of specifically targeting CyaA to cells of the immune system. 
Ultimately the interaction of CyaA with immune effector cells will be of most interest 
because the evidence suggests that it is a weak haemolysin which is ineffective on 
human erythrocytes. Nevertheless erythrocytes and model membrane systems such as 
liposomes, will continue to be useful tools for studying the interaction of CyaA with 
cell membranes.
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A P P E N D IX  1
CYCLODEXTRIN LIQUID MEDIUM (CD)
(Imaizumi e ta l , 1983 & 1984)
Cyclodextrin liquid medium (CD)
L-glutamate (monosodium salt) 10.72 g
L-proline 0.24 g
Sodium chloride (NaCl) 2.5 g
Potassium dihydrogen orthophosphate (KH2 PO4 ) 0.5 g
Potssium chloride (KCl) 0 . 2  g
Magnesium chloride (MgCh • 6 H2 O) 0 . 1  g
Calcium chloride (CaCl2  • 2 H2 O) 0 . 0 2  g
Tris 6.075 g
Casamino acids ^ 1 0  g
Heptakis [2,6-O-Dimethyl p-cyclodextrin (MepCD)] 1 . 0  g
 ^Casein acid hydrolysate ( Peptone No.5, Gibco)
Dissolve CD medium in 900 ml distilled water and adjust pH to 7.4 with cone. HCl 
and make up to 990 ml with distilled water. Autoclave and store at 4°C. Before use 
add 1 0  ml of sterile vitamin supplements (see below).
Vitamin supplement
L-cysteine 0.4 g
Ferrous sulphate (FeS0 4  . 7 H2 O) 0.1 g
Ascorbic acid 0.2 g
Nicotinic acid 0.04 g
Glutathionine 1.5 g
Dissolve in 100 ml distilled water, and filter sterilise through a Millipore filter 
(0.45pm) before use..
157
A P P E N D IX  2
2 X YEAST TRYPTONE MEDIUM (2 X YT)
(Sambrook, 1989)
2 X Yeast Tryptone Broth
Tryptone 16 g
Yeast Extract 10 g
NaCl 5 g
Distilled water 900 ml
Adjust pH to 7.0 with 5N NaOH, make volume up to 1000 ml with distiled water, 
and autoclave.
2 X Yeast Tryptone Agar
As above but containing 1.2% Technical Agar (Oxoid)
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A P P E N D IX  3
SDS-PAGE BUFFERS AND STOCK SOLUTIONS
(Laemmli, 1970)
STOCK SOLUTIONS
Acrylamide / Bis
Aciylamide 30 g
N,N-Methylene-bis-acrylamide 0.8 g
Dissolve in 100ml (final volume) distilled water, and filter before use.
Lower buffer
Tris 18.1 g
SDS 0.4 g
Distilled water 70 ml
Adjust pH to 8.9 with cone. HCl and make up to 100 ml with distilled water.
Upper buffer
Tris 6.06 g
SDS 0.4 g
Distilled water 70 ml
Adjust pH to 6.8 with cone. HCl and make up to 100 ml with distilled water.
Solubilising buffer
Glycerol 10 ml
2-mercaptoethanol 5 ml
SDS 3.0 g
Bromophenol blue 0.01 g
Make to 100ml with Upper buffer (1 in 8 dilution).
Running Buffer
Tris 6.06 g
Glycine 28.8 g
SDS 2.0 g
Distilled water 1800 ml
Adjust pH to 8.3 with cone. HCl and make volume up to 2 Litres with
distilled water.
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Coomassie-Blue staining solution (xlO)
Coomassie-Blue R250 (BDH) 1.25 g
50 % (v/v) methanol 454 ml
Glacial acetic acid 46 ml
Filter and dilute 1 in 10 in distilled water before use.
Destaining solution
Methanol 50 ml
Glacial acetic acid 75 ml
Distilled water 875 ml
GEL PREPARATION
Lower separating gel - 7.5 %
Lower buffer 10 ml
Distilled water 20 ml
Aciylamide / Bis 10 ml
Ammonium persulphate (10%)^ 200 pi
TEMED 20 pi
 ^freshly prepared
Upper stacking gel - 4.5 %
Upper buffer 5 ml
Distilled water 12 ml
Acrylamide / Bis 3 ml
Ammonium persulphate (10%)^ 60 pi
TEMED 40 pi
 ^freshly prepared
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A P P E N D IX  4
RESORCINOL REAGENT
(Kates, 1972)
Preparation of Reagent
Dissolve 2 grams of resorcinol in 100ml of water (stable solution). At least 4 h 
before use add 10ml of this solution to 80ml of cone. HCl (Analar reagent grade), 
containing 0.5ml of 0,1M copper sulphate (2.5g CUSO4  • H2 O in 100ml of water), 
and dilute mixture to 1 0 0 ml with water.
Procedure
Spray the dried plate with the resorcinol reagent: cover the sprayed TLC plate 
carefully with a glass plate and heat in an oven at 120°C. Gangliosides or sialic acid 
derivatives appear as a blue-violet spots,
&
